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ABSTRACT
FUNCTIONAL SPECIFICITY AND DESIGN OF TRANSCRIPTION FACTORS:
THE OCT-1 HOMEODOMAIN
by
Joel Leonard Pomerantz
Submitted to the Department of Biology on August 11, 1995
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
The development and differentiation of eukaryotic organisms depends upon
transcriptional regulation exerted by homeodomain proteins; however, the mechanisms
that determine the functional specificity of these factors remain largely undefined. The
human Oct-1 homeodomain protein regulates Herpes Simplex Virus-1 (HSV) gene
expression by participating in the formation of a multiprotein complex (C1 complex) that
activates the HSV a (immediate early) genes. The C1 complex, composed of the viral
aTIF protein, Oct-i, and the cellular C1 factor, forms on the a/IE element (5'-
ATGCTAATGATATTCTTTGG-3'). A panel of Oct-1 homeodomain variants was
generated and assayed for the ability to interact with aTIF and participate in C1 complex
formation. The results indicated that in complex formation the homeodomain is
recognized on the surface of helices 1 and 2 by the viral aTIF protein. The differing
abilities of Oct-1 and the related Oct-2 protein to participate in complex formation
correlated with a single amino acid difference in helix 1 of their homeodomains. This
scenario models how protein-protein interactions at the surface of a DNA-bound
homeodomain can determine functional specificity.
The Oct-i homeodomain contacts DNA in the major groove through interactions
which are common to many homeodomain factors. Asparagine 51 contacts an adenine
and valine 47 contacts a thymine at conserved positions in a core homeodomain binding
site (5'-TAAINN-3'). An Oct-1 POU domain bacterial expression library was generated
in which residues 47 and 51 in the homeodomain were randomized. The library was
screened with probes containing the wild-type octamer sequence (5'-ATGCAAAT-3'),
and with probes containing substitutions at the recognized positions. Of many
possibilities examined, the wild-type combination of residues and base-pairs provided
interactions with the highest affinity and specificity. This suggests that the fold and the
DNA-docking of the homeodomain constrain what residues can be used as determinants
of DNA recognition.
Structure-based design was used to retarget the Oct-1 homeodomain to a novel
sequence. Computer modeling predicted how the homeodomain might be fused to zinc
fingers 1 and 2 from Zif268 to create a chimeric protein, ZFHD1. ZFHD1 displayed
novel DNA-binding specificity in vitro, and, when fused to an activation domain,
activated transcription in a sequence-specific manner in vivo. On the appropriate DNA
element, ZFHD1 efficiently nucleated formation of a C1 complex in vitro and in vivo.
This indicated that when targeted to DNA with high affinity and specificity, the
homeodomain of Oct-i mediates all the protein-protein interactions that are necessary to
efficiently recruit aTIF and C1 factor into a functional enhancer complex.
Thesis Supervisor: Dr. Phillip A. Sharp, Salvador E. Luria Professor and Head,
Department of Biology
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CHAPTER I
INTRODUCTION AND OVERVIEW
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A fundamental characteristic of transcription factors is their modularity, the fact
that they are composed of domains which are functionally and structurally independent.
This was first discovered as the ability to cut and paste transcriptional activation domains
onto heterologous DNA-binding domains (Brent and Ptashne, 1985), but domains have
also been described which mediate other functions, including repression (e.g. Han and
Manley, 1993), hetero- or homodimerization (e.g. Landschulz et al., 1988), and ligand
binding (Evans, 1988). The function of a transcription factor is determined by the
integration in one molecule of the separate functions of these modules. At present, there
is no evidence that sequence-specific transcription factors catalyze a chemical reaction.
Rather they function via intermolecular binding. The specificity of a transcription factor
thus results from the molecular interactions specified at the surfaces of their domains.
The DNA-binding domain, or module, determines function in the simplest
scenario by presenting a surface which docks against DNA and recognizes a particular
sequence of base pairs. This interaction specifies which cis-elements in the genome the
transcription factor can recognize and therefore which genes it will regulate. However, in
many cases, the DNA-binding domain does more. This thesis describes the
characterization of protein-DNA and protein-protein interactions through which the Oct-i
homeodomain achieves functional specificity. Four main themes emerge from the
experiments presented in detail in the four succeeding chapters:
1) A DNA-binding domain can determine the functional specificity of a
transcription factor through protein-protein interactions, a mechanism distinct
from its DNA-binding specificity.
2) The fold of a DNA-binding domain and the manner in which it docks to DNA
can constrain what amino acids are used as determinants of DNA recognition.
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3) The modularity of transcription factors is a design tool. A structural
understanding of domain-DNA interactions allows straightforward design of
chimeric domains with novel specificities.
4) A designed transcription factor can be a research tool. The structure-based
design of chimeric proteins allows a DNA-binding domain to be isolated for study
from the rest of the protein from which it is derived, and the ability to change its
DNA-binding specificity without introducing mutations at the protein-DNA
interface.
The intention of this chapter is to place the experiments presented in the body of
the thesis into a contextual framework in three relevant fields: 1) Herpes Simplex Virus
gene expression; 2) the biology of the homeodomain family of regulators; 3) transcription
factor design.
HERPES SIMPLEX VIRUS GENE EXPRESSION
The Herpes Simplex Virus (HSV)-1 is a 150kb double stranded DNA virus that
infects a wide variety of cells in culture, replicating over the course of an 18 hour life
cycle leading to the rapid destruction of the cells. In humans, after initiating a primary
infection, the virus migrates through nerve axons to sensory ganglia, where it establishes
latency. Reactivation of the virus occurs periodically over a lifetime in response to a
variety of environmental factors (Roizman and Sears, 1991).
The HSV life cycle is controlled by a cascade of gene expression that begins upon
infection with the transcription of the a or immediate early genes, the induction of which
requires no new protein synthesis. The a genes encode regulatory proteins that
transactivate the expression of (early) genes, which encode proteins that are involved in
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nucleic acid metabolism and are required for viral DNA synthesis. Following the onset
of viral DNA replication the y (late) genes, which encode the structural proteins of the
virus, are transcribed.
Early studies demonstrated that the induction of a gene expression was dependent
on the viral aTIF (a-trans-induction factor, also known as VP16, Vmw65, ICP25), a
structural protein located in the tegument portion of the virus (between the capsid and the
envelope) (Post et al., 1981; Campbell et al., 1984; Pellet et al 1985). After infection,
aTIF enters the nucleus of the host cell and activates transcription through what was
originally called the aTIC (a-trans-induction-cis site), an element found in one to three
copies in the regulatory regions of the five a genes (Mackem and Roizman, 1982 a-c;
Kristie and Roizman, 1984). This element is now more commonly referred to as the a/IE
element or the TAATGARAT motif because of the central portion of its sequence
consensus (5'-GYATGNTAATGARATITCYTTGNGGG-3'). Analysis of aTIF failed to
demonstrate specific high affinity binding of the protein to the a/IE element (Marsden et
al., 1987), and it was later found to associate only in the presence of cellular factors
(Kristie and Roizman, 1987; Preston et al., 1988; O'Hare and Goding, 1988; Gerster and
Roeder, 1988). One of these was identified as the previously described Oct-i factor, and
the other was purified and cloned on the basis of its role in a/IE association and is called
the C1 factor. Oct-i, aTIF, and the C1 factor assemble into a complex on the or/IE
element (C1 complex)(Figure 1). These factors and their role in C1 complex formation
are briefly described below.
aTIF
aTIF is a 490 amino acid protein, best known for the extremely potent acidic
transcriptional activation domain contained in its C-terminal 80 amino acids (Triezenberg
et al., 1988; Sadowski et al., 1988). The activation domain is required for a/IE
transactivation, but is dispensable for C1 complex formation. Two regions of the protein
9
Figure 1. Components and topology of the C1 complex. (A) A schematic representation
of the viral aTIF protein. The regions shown in blue, when deleted, intefere with C1
complex formation. The C-terminal acidic activation domain is indicated (A). (B) A
schematic representation of the Oct-1 protein. Glutamine rich regions of an activation
domain in the N-terminal portion are indicated (Q). The activation domain that appears
to be specialized for function at snRNA promoters is located at the C-terminus (B). The
bipartite POU domain is composed of a POU-specific domain (residues 279-354, green),
a homeodomain (residues 479-439, red), and a 24 residue linker in between. (C) A
schematic representation of the C1 factor precursor protein showing the locations of the
20 amino acid repeats that are targets for proteolytic cleavage. The products of cleavage
appear to remain associated (Wilson et al., 1993). The repeat core consensus is
VCSNPPCETHETGTTN/HTATT. N-terminal sequencing of C1 factor subunits suggests
that cleavage occurs between the underlined residues in repeats 2, 3, 5, and 6 (Kristie et
al., 1993). The repeat indicated by a D contains a core sequence which diverges from the
consensus. The numbers refer to the location of the first residue in the 20 amino acid
core in each repeat. (D) A schematic representation of the C1 complex assembled on the
a/IE element. The depicted interaction of the POU domain with the 5' portion of the
element is based on the coordinates of Klemm et al. (1994). The POU-specific domain
(green) and the homeodomain (red) are connected by a 24 residue linker that is not visible
in the crystal structure and is therefore indicated by a dashed line. DNA subsites for the
POU subdomains are indicated in the sequence of the a/IE element below in matching
colors. The aTIF and C1 factors associate with the 3' portion of the element (shaded
base-pairs) but their structures are unknown. aTIF is thought to contact the DNA in this
region but it is not known whether the C1 factor makes any contact with the DNA.
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are important for complex formation, one between residues 173 and 241, the other
between 317 and 403 (Ace et al., 1988; Werstuck and Capone, 1989; Greaves and
O'Hare, 1989, 1990). A short peptide comprising residues 360-367 has been shown to
inhibit complex formation (Hayes and O'Hare, 1993), and Stern and Herr (1991) have
demonstrated an interaction between the DNA-bound POU domain and a peptide
containing residues 360-391. Independent DNA binding of aTIF to the TAATGARAT
core of the a/lE element has been observed, but only at high protein concentrations
(roughly 50 fold higher than is necessary to form the C1 complex) (Kristie and Sharp,
1990).
Oct-i
The Oct-i transcription factor is a founding member of the POU domain family of
factors (Herr et al., 1988), a subfamily of the larger homeodomain class of regulatory
proteins. The protein is 743 amino acids long, composed of N- and C-terminal activation
domains, and a central DNA-binding domain, the POU domain (Sturm et al., 1988). Oct-
1 is ubiquitously expressed and has been implicated in the regulation of many cellular
genes. An octamer element is critical for the ubiquitous expression of the small nuclear
(sn)RNA genes (Ares et al., 1987; Bark et al., 1987; Carbon et al., 1987; Murphy et al.,
1987), the cell-cycle-specific expression of the histone H2B gene (Sive et al., 1986;
Fletcher et al., 1987; LaBella et al., 1988), and the tissue-specific expression of the
interleukin-2 (Ullman et al., 1991) and immunoglobulin genes (Mizushima-Sugano and
Roeder 1986; Staudt et al., 1986; Scheidereit et al., 1987; Wirth et al., 1987; LeBowitz et
al., 1988; Muller et al., 1988; Gerster et al., 1987). Viral genomes also exploit the
octamer element, which is found in the a/IE element of HSV, the SV40 enhancer
(Davidson et al., 1986) and in the adenovirus origin of DNA replication (Pruijn et al.,
1986, 1987; O'Neill et al., 1988).
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Despite the implication of Oct-i involvement in this wide spectrum of disparate
regulatory scenarios, the activation domains of the protein appear to be specialized for
function in the context of an snRNA promoter, and work only weakly in the context of an
mRNA promoter (Tanaka et al., 1992). This suggests the possibility that other regions of
the protein, namely the POU domain, are the functionally relevant portions in non-
snRNA regulatory contexts. Indeed, the POU domain has been proven to be necessary
and sufficient for activity at the origin of adenovirus DNA replication (Verrijzer et al.
1990a), and, as will be discussed, at the a/IE element. The POU domain of Oct-i also
has been shown to physically interact with several factors, including the glucocorticoid
receptor (Kutoh et al., 1992), Pit-l(Voss et al., 1991), TATA-Binding Protein (Zwilling
et al., 1994), PTF (a regulator of snRNA genes; Murphy et al., 1992), and High Mobility
Group protein-2 (Zwilling et al., 1995).
C1 factor
The C1 factor was identified biochemically as the cellular activity required for
aTIF association with an Oct-l:a/IE element complex (Kristie et al., 1989; Xiao and
Capone, 1990; Katan et al., 1990). The activity is present in extracts of insect cells, and
every mammalian cell so far examined, suggesting a strong evolutionary conservation of
function. The C1 factor was purified from HeLa nuclear extracts using a C1 complex
formation assay and was found to consist of a group of polypeptides ranging in molecular
weight from 68 to 155 kilodaltons (Kristie and Sharp, 1993; Wilson et al., 1993). Peptide
sequencing of tryptic digests led to the isolation of a 8.2 kb cDNA which appears to
encode a large precursor protein that is proteolytically processed (Wilson et al., 1993;
Kristie et al., 1995). The precursor protein is 2035 amino acids in length and has no
homology to any known sequence. The most remarkable feature of the protein is the
presence of 7 repeats of a 20 amino acid motif in its central portion. These repeats appear
to be targets for site-specific proteolytic cleavage that produces a heterogeneous set of N-
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and C-terminal fragments which remain associated. The cellular function of the C 1 factor
is completely unknown.
The C1 complex
The 5' portion of the a/E element is recognized by the POU domain of Oct-i, a
bipartite DNA binding domain composed of a POU-specific domain (which binds the
ATGC subsite) and a homeodomain (which binds the TAATGA subsite) (Kristie and
Sharp, 1990; Verrijzer et al., 1990b). Oct-i can associate with the element with high
affinity in a stable protein-DNA complex, but neither aTIF nor the C1 factor display
independent high affinity DNA binding. Evidence of the interaction of aTIF and C1
factors with the 3' portion of the element (ATGCTAATGATATTCTTTGG) consists of
the 3' extension of the Oct-i footprint when aTIF and C1 factor are added to an Oct-
1:DNA complex, and the effect of mutations in this 3' portion which abrogate complex
formation without affecting Oct-i affinity. The C1 factor associates with aTIF in
solution, but neither factor appears to interact with Oct-1 in the absence of DNA (Kristie
and Sharp, 1990).
The function of the C1 complex appears to be to tether the extremely potent
activation domain of aTIF to the a/IE element only in the presence of the Oct-1 and C1
factors. Why does HSV set up such a scenario? It is clear that the ensemble of protein-
protein and protein-DNA interactions in the C1 complex make aTIF tethering highly
sequence specific for the a/IE element. The requirement for both the 5' portion of the
element, an octamer site homolog, and the 3' portion, which is recognized by aTIF and
possibly the C1 factor, may ensure that aTIF-mediated activation will only occur on viral
a promoters and not at cellular promoters which may individually be recognized by
octamer binding proteins or other cellular proteins that might act in concert with the C1
factor. Interestingly, Oct-1 DNA-binding activity has been shown to be regulated by
phosphorylation in a cell-cycle-dependent manner. Phosphorylation occurs at the onset
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of M phase at a residue (serine 7) in the N-terminal arm of the homeodomain, inactivating
DNA-binding by the POU domain (Segil et al., 1991; Roberts et al., 1991). Perhaps the
dependence of C1 complex formation on Oct-i DNA-binding couples the cascade of viral
gene expression to the cell cycle progression of the infected cell.
Most intriguing is to consider the dependence of C1 complex formation on the
cellular C1 factor. In this light, it is striking to compare aTIF to the E1A gene product of
adenovirus, another protein which transactivates viral gene expression but must rely upon
protein-protein interactions with cellular factors to associate with a promoter. The study
of ElA-associated proteins has yielded the characterization of a number of proteins which
are fundamentally important for cell-cycle regulation and proliferation (Dyson and
Harlow, 1992). Among those that directly bind to E1A are the retinoblastoma tumor
suppressor pRb, and two related proteins p107 and p130. It is thought that binding of
E1A to these cellular proteins inactivates their function, allowing progression of the cell
into S phase. E1A association is independent of DNA-binding, as is the association of
aTIF with the C1 factor. The conservation of C1 factor activity in insect and mammalian
cells suggests a fundamental role for this protein in cellular function. The most exciting
possibility is that the C1 factor represents a viral target as interesting and important as
those targeted by adenovirus through E1A.
The role of the Oct-i homeodomain in C1 complex formation
The availability of cDNA clones of Oct- allowed the dissection of which regions
of the protein are necessary for C1 complex formation. Initial studies demonstrated that
the POU domain alone possessed equivalent DNA-binding affinity and efficiency at
complex formation as full length Oct-l (Kristie et al., 1989; Stern et al., 1989). The
homeodomain portion of the POU domain alone could nucleate C1 complex formation on
the a/IE element, but only at high protein concentrations (100 fold higher than was
necessary for the intact POU domain) (Kristie and Sharp, 1990). A third important
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observation was that Oct-2, a related POU domain protein, formed the C1 complex with a
100-fold lower efficiency, despite a high homology to Oct-1 in the POU domain and an
indistinguishable DNA binding specificity (Kristie et al., 1989). Finally, it was not
known which component of the complex was responsible for the specific interaction with
Oct-i.
The experiments described in Chapter 2 established that the surface of the DNA-
bound Oct-1 homeodomain is recognized in C1 complex formation by the viral aTIF
factor. The determinants for the interaction lie on homeodomain helices 1 and 2, and a
single amino acid difference between Oct-1 and Oct-2 in helix 1 of the homeodomain
accounts for their differing abilities to cooperatively interact with aTIF and form the C1
complex. This amino acid does not affect DNA-binding affinity or specificity. The
experiments presented in Chapter 5 established that the 60 amino acid Oct-1
homeodomain contains all of the determinants responsible for the Oct-l-mediated
protein-protein interactions that are required for complex formation. A designed
transcription factor that can target the homeodomain to DNA with high affinity and
specificity in the absence of the rest of the Oct-i protein can nucleate formation of the C1
complex with an efficiency equivalent to the intact POU domain.
The differing abilities of Oct-i and Oct-2 to participate in C1 complex formation
provides a paradigm that explains how two transcription factors with extremely similar
DNA-binding specifities could mediate distinct functional effects, and how a single cis-
element could be important for the disparate regulation of many genes. It is possible that
cellular analogs or homologues of aTIF associate with Oct-1 or Oct-2 to confer
temporally or spatially restricted activity on the octamer element in the context of a
particular promoter. There is evidence that this is the case for some promoters. The
unique activity of the immunoglobulin octamer element in B cells has recently been
attributed to the existence of the B-cell specific protein OCA-B (OBF-1, Bob-1) (Luo et
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al., 1992; Gstaiger et al., 1995; Strubin et al., 1995). OCA-B associates with the POU
domain of either Oct-1 or Oct-2 and contains an activation domain. OCA-B does not
appear to have independent DNA-binding activity, and association with OCA-B does not
affect the off-rate of Oct-1. The transcriptional induction of the interleukin-2 gene in
response to antigenic stimulation of T cells is mediated by an antigen-receptor response
element (ARRE-1) in the IL-2 enhancer. Oct-i and an activity that is induced by
activation, OAP4 0 (octamer-associated protein 40), associate with the element (Ullman et
al., 1991). OAP4 0 possesses sequence specificity for the 5' portion of the ARRE-1 and
decreases the off-rate of Oct-1. The factor has been identified as a mixture of Jun D and
c-Jun factors (Ullman et al., 1993). It has yet to be determined which residues of Oct-1
mediate the interaction with OCA-B or OAP4 0 , but it would not be surprising if the
homeodomain were involved.
In its role in HSV a/IE gene expression, the Oct-1 homeodomain can be thought
of as a module with two surfaces, one that docks against DNA, the other which presents
determinants for protein-protein interactions. This may be a general picture of how
homeodomains function in other systems. As described in the following section, some
examples of homeodomain function have discrete biochemical parallels with the HSV
scenario, while others appear as though they will.
HOMEODOMAIN BIOLOGY
Homeodomain proteins comprise a large family of "master regulatory" proteins
that control cell-type specification and organization of the body plan in eukaryotic
organisms as evolutionarily distant as yeast and humans (Gehring, 1987; Scott et al.,
1989; Affolter et al., 1990; Kenyon, 1994;, Lawrence and Morata, 1994; Krumlauf,
1994). They are called "master regulatory" because in general, they are thought to act as
transcription factors epistatic to cascades of gene expression which ultimately produce
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the structural gene products that differentiate one cell type from another, or one region of
the organism from adjacent tissues. Presence of the 60 amino acid homeodomain DNA-
binding module defines the family, which includes hundreds of proteins that can be
grouped into subfamilies by homology within the homeodomain.
The structure and DNA-binding properties of homeodomains have been
vigorously studied. NMR and crystal structures of homeodomain proteins, most of them
in the presence of DNA, have demonstrated that even minimally related homeodomains
adopt a conserved structure and mode of docking to DNA (Kissinger et al., 1990; Otting
et al., 1990; Wolberger et al., 1991; Billeter et al., 1993; Klemm et al., 1994) . The
domain is composed of an N-terminal arm which contacts DNA in the minor groove, and
three a helices, the third of which makes base-specific contacts in the major groove.
Residues throughout the domain contact the sugar-phosphate backbone of DNA. Many
homeodomains display similar DNA sequence specificities, and bind to a sequence of the
form 5'-TAATNN-3'. The first two base pairs are recognized in the minor groove
(TAATNN), and the last four in the major groove (TAATNN) (Laughon, 1991). There
are several classes of homeodomain factors which contain another DNA binding domain
in addition to the homeodomain in the same protein. A given protein may contain a
POU, paired, cut, Lim, or C2H2 zinc finger domain, or even other homeodomains
(Laughon, 1991).
Homeodomains and the body plan
Homeodomain proteins were first discovered and perhaps, are best known, as the
molecular basis for homeotic mutations, i.e. mutations which cause the transformation of
one body part into another. The genes encoding these proteins are found in clusters in the
genomes of nematodes, arthropods, and vertebrates (Kenyon, 1994). In Drosophila,
eight genes comprise two complexes, the Antennapedia complex (ANT-C) and bithorax
complex (BX-C). C. elegans contains a single cluster with four genes, while mice and
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humans each possess four clusters containing a total of 38 genes. Based on sequence
homology, many individual genes in each cluster can be grouped across species into 13
paralogous groups (Krumlauf, 1994).
In flies, the genes in the ANT-C and BX-C complexes are referred to as homeotic
selector genes. These genes are responsible for the development of parasegments 1
through 14 in the embryo, which ultimately give rise to the posterior head, thorax and
abdomen of the fly (Lawrence and Morata, 1994). In vertebrates, the genes are referred
to in a Hox nomenclature, and mutations in Hox genes affect many tissues, including the
axial skeleton, neural crest, central nervous system, and limbs (Krumlauf, 1994). The
functional relationship between vertebrate and invertebrate homeodomain proteins has
been highlighted by the observation that some mammalian Hox genes and their
Drosophila homologues induce similar phenotypes when expressed ectopically in
Drosophila embryos (Malicki et al., 1990; McGinnis et al., 1990).
The physical order of the genes in the cluster, 5' to 3', correlates with the
expression pattern of the genes along the anterior-posterior axis, and with the temporal
order of expression, from early to late in embryonic development. The genes have
overlapping regions of expression, and each gene results in a particular phenotype when
mutated or expressed ectopically. A key feature of the homeotic selector genes is that the
effect of mutation or ectopic expression of a particular gene is dependent on what other
homeotic genes are expressed in the particular region of the embryo affected. In both
flies and mice, there appears to be a functional dominance of posterior genes over
anterior genes expressed in the same domain, a phenomenon referred to as phenotypic
suppression or posterior prevalence (Morata, 1993).
There are few precise molecular explanations for how these homeodomain
proteins exert their specific actions (Hayashi and Scott, 1990; Kornberg, 1993). Some
have begun to address this issue by first defining the domains of each protein which are
important in an ectopic (ubiquitous) expression assay. This has been done by taking two
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homeodomain proteins that demonstrate different phenotypes in the assay and observing
the effects of swapping domains and amino acid differences. In several studies, the
homeodomain has proven to be critical for functional specificity, as well as other regions
C-terminal or N-terminal to the homeodomain (Kuziora and McGinnis, 1989; Gibson et
al., 1990; Malicki et al., 1990; Mann and Hogness, 1990; McGinnis et al., 1990;
Furukubo-Tokunaga et al., 1992).
Since the homeodomain serves as the DNA-binding domain for these proteins it is
not surprising that this region would be critical for the specificity of function. The DNA-
binding specificity of the domain might simply determine which downstream genes the
protein will regulate, ultimately leading to a specific phenotype. However, many
homeodomain proteins have extremely similar DNA-binding specificities (Laughon,
1991). All of the homeodomains used in the specificity studies are highly homologous in
the third helix of the homeodomain which recognizes base-pairs in the major groove.
Residues in this helix that correspond to those shown in the homeodomain:DNA crystal
structures to be contacting DNA are identical in these proteins. Thus, it is likely that a
mechanism other than intrinsic DNA-binding specificity is responsible for the different
phenotypic effects of these proteins.
Four studies have performed swaps within the homeodomain to delineate the
amino acids that are important for functional specificity. In the study that examined
differences between Deformed (Dfd) and Ultrabithorax (Ubx) homeodomains (Lin and
McGinnis, 1992), homeodomain residues -1, 1, 2, 4, 6, and 7 in the N-terminal arm were
shown to be critical for determining phenotype. Swapping these residues appeared to
have no effects on in vitro DNA-binding activity that correlated with in vivo activity.
The four differences between Antennapedia (Antp) and Sex combs reduced (Scr)
homeodomains, at residues 1, 4, 6, and 7, appeared to account for their differing
functional specificities in two independent studies (Zeng et al., 1993; Furukubo-
Tokunaga et al., 1993). Finally, in a study that examined the differences between Ubx
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and Antp, residues -1, 2, 22, 24, 56, and the region C-terminal to the homeodomain were
shown to be important (Chan and Mann, 1993).
Since the N-terminal arm makes contacts to DNA in the minor groove, the
recurrence of N-terminal arm residues in these studies suggests the possibility that the
DNA-binding properties of the homeodomain may contribute to functional specificity.
Some studies have detected slight differences in DNA-binding affinity or specificity
between homeotic selector gene products (Ekker et al., 1992, 1994). However, most of
the critical residues in these biological specificity studies map in the three-dimensional
structure to surfaces which would be accessible for the interaction with other proteins
when the homeodomain binds DNA. Protein-protein interactions involving these
residues could affect target specificity or effector function. As has been discussed,
protein-protein interactions determine the differing abilities of Oct-i and Oct-2 to
participate in the C1 complex, and furthermore, even a single amino acid difference
between the two proteins is sufficient to determine functional specificity for this
regulatory event.
The elucidation of whether protein-protein interactions are as important for
Drosophila homeodomains must wait in most cases until more of the target genes have
been identified. However, the characterization of the functional differences between Ubx
and Antp has resulted in the identification of extradenticle (exd) as a protein that
differentially interacts with these homeodomain proteins to affect their target specificity.
The product of the extradenticle gene had been thought to act as a "cofactor" for
homeodomain function because mutations in this gene produced homeotic
transformations in thoracic and abdominal segements without altering the expression
patterns of homeotic selector genes (Peifer and Wieschaus, 1990). Two studies (Chan et
al., 1994; van Dijk and Murre, 1994) demonstrated that exd selectively interacts with
Ubx, as compared to Antp, in cooperative binding to the enhancer of the decapentaplegic
gene. The interaction between exd and Ubx involved determinants of Ubx that were
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shown to be critical in the ectopic expression assay. One of the critical determinants in
Ubx was at homeodomain position 22 (numbering scheme of Qian et al., 1989). The
critical difference between Oct-i and Oct-2 in C1 complex formation lies at position 22.
Interestingly, exd is a divergent homeodomain protein, related in sequence to the
al and a2 homeodomain proteins of yeast. In addition to Ubx, exd also cooperatively
interacts with abdominal-A and engrailed homeodomain proteins, through regions N-
terminal to the homeodomain (for Ubx and abd-A), and C-terminal to the homeodomain
(engrailed) (Van Dijk and Murre, 1994). The existence of exd homologs in humans
suggests that the cooperative interaction between homeodomains may be a broadly
conserved mechanism for determining the specificity of homeodomain action.
Although homeodomain proteins may be best known as critical players in the
morphogenesis of animals, many homeodomain proteins control cell-type-specific
functions. Two examples, one from human disease, the other from yeast, are illustrative.
The first example, Pit-1, is pertinent to the discussion of the role of the Oct-i in HSV
gene regulation because it is a well-characterized POU domain family member and
because like Oct-i, mutations have been found in the DNA-binding domain that alter
effector function without compromising DNA binding. The second example, that of the
a2 and al homeodomain proteins, is relevant because the system is one of the best
examples of how protein-protein interactions with homeodomain proteins can enhance
DNA target specificity, and because the homeodomain surface is important for one of
these interactions.
Pit-1
The Pit-1 transcription factor is critical for anterior pituitary development (Voss
and Rosenfeld, 1992). As is the case for many homeodomain proteins, natural mutations
have been observed, leading to the description of a specific overt phenotype. In humans,
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patients with combined pituitary hormone deficiency (CPHD) suffer from a spectrum of
symptoms that often include irreversible mental and growth retardation. Some patients
have been found to have alleles of Pit- 1 with mutations in the POU domain. One of these
is a nonsense mutation in the middle of the POU domain (Tatsumi et al., 1992). Another
causes a substitution of tryptophan for arginine at position 58 in the homeodomain, which
does not interfere with DNA binding but does abrogate the ability of the protein to
transactivate in a tissue culture assay (Radovick et al., 1992). These patients have a
complete absence of three cell types in the anterior pituitary: somatotrophs, which
produce growth hormone, lactotrophs, which produce prolactin, and thyrotrophs, which
produce thyroid-stimulating hormone. The same hormone deficiencies are observed in
the Snell mouse dwarf mutation dw, which is caused by a mutation at homeodomain
position 48 from tryptophan to cysteine, which destroys the ability of the protein to bind
DNA (Li et al., 1990). Binding sites for Pit-i are found in the promoter regions of the
prolactin and growth hormone genes, and the expression of the growth hormone releasing
factor receptor, which controls somatotroph proliferation, is reduced in Pit-1 deficient
animals (Lin et al., 1992).
A distinct Pit-1 mutation has been discovered in two Dutch families. Affected
(homozygous) individuals exhibit hypopituitarism without hypoplasia and possess an
allele of Pit-i which contains a proline for alanine substitute in helix 2 of the POU-
specific domain (Pfaffle et al., 1992). This substitution does not affect DNA binding but
does reduce the transactivation function. Thus, different muations in the POU domain can
lead to different phenotypes or clinical states. The Pit-i mutations which do not affect
DNA-binding are located on solvent-exposed surfaces of either the POU-specific domain
or the homeodomain. There must be factors which recognize these residues and are
required for transactivation in certain, perhaps as yet undefined, promoter contexts. The
recognition of the surface of the Oct-1 homeodomain in C1 complex formation may
provide a relevant model for how different mutations in Pit-1 might differentially affect
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the expression of downstream genes that are critical for the development and function of
the anterior pituitary.
a2 and al
Cell type-determination in S. cerevisiae is dependent on two homeodomain
proteins, a2 and al (Johnson, 1992). a2 is expressed in a cells, al in a cells, and both are
expressed in the diploid a/a cell. a2 binds cooperatively with the MCM1 protein at
operators for a-specific genes (asg), leading to their repression in a and a/a cells. In a/a
cells, a2 and al bind cooperatively to the operators of haploid-specific genes (hsg),
causing their repression.
In the recognition of the asg operator, MCM1 binds as a dimer in between two
binding subsites for a2. In the absence of MCM1, a2 can bind as a dimer to artificial
operators containing subsites in several different spacings and orientations (Smith and
Johnson, 1992). It appears that cooperative interactions between a2 and MCM1 can
occur only with the specific spacing and orientation of the subsites in the asg operator.
The cooperative interaction with MCM1, thus enhances the target specificty of a2. The
interaction involves a "hinge" region of a2 which is N-terminal to the homeodomain
(Vershon and Johnson, 1993).
A similar cooperative interaction between a2 and al determines target specificty
of the two proteins for hsg operators (Goutte and Johnson, 1988; Mak and Johnson,
1993). Independent binding of a2 to the hsg operator is very weak, independent al
binding is undetectable. When the two proteins heterodimerize on DNA, the region of a2
C-terminal to the homeodomain ("a2 tail") undergoes a transition from disorder into a
helical conformation (Phillips et al., 1994). This helix interacts with the solvent exposed
surface of helices 1 and 2 of the al homeodomain (T. Li and C. Wolberger, personal
communication).
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Thus, the efficient targeting of the a2 homeodomain protein to a-specific genes
and haploid-specific genes depends upon cooperative protein-protein interactions with
MCM1 and the al homeodomain. The interaction with al is similar to the aTIF-Oct-1
interaction because in both cases the surfaces of helices 1 and 2 are contacted. It would
be interesting to compare the surfaces of al and Oct- homeodomains that are recognized
by the a2 tail, and aTIF, respectively. Perhaps a structural transition in aTIF,
concomitant with C1 complex formation, parallels the transition of the a2 tail as it
interacts with al. If this transition is triggered by binding of aTIF to the C1 factor, it
would provide a satisfying explanation for the physical requirement for the C1 factor in
complex assembly.
TRANSCRIPTION FACTOR DESIGN
The recognition of the Oct-1 homeodomain in C1 complex formation suggested
the possibility that the surface of the Oct-i homeodomain was recognized as a part of the
regulation of cellular genes which rely on the octamer element. One way to address this
experimentally would be to set up a cell-culture cotransfection system with an array of
reporter vectors containing the appropriate enhancer or promoter regions of octamer-
regulated genes. If one could establish an assay in which stimulation of reporter gene
expression was dependent on the cotransfection of an Oct-l-expressing plasmid, one
could assay the effects of mutations on the surface of the homeodomain in a
straightforward manner. Such a system would allow the survey of many cellular
promoters each of which might require a particular cell type for expression.
A barrier to this approach is the ubiquitous expression of Oct-i in most, if not all
human cell lines. Any transfected Oct-i variant would have to compete for binding to the
reporter with the wild-type, endogenous protein, which would already be present when
the reporter vector entered the cell. This notion led to the attempts decribed in Chapters
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3 and 4 to develop a variant of Oct-1 which could target the homeodomain to a DNA
sequence that the wild-type Oct-1 could not recognize. This novel sequence would be
inserted in the reporter vectors in place of the octamer element, and together with the
altered-specificity Oct-1 variant, the system would be independent of endogenous
octamer-binding activity. Two approaches were followed to obtain the altered-specificity
variant. The first relied upon the assumption that specificity could be changed by the
mutation of residues that mediate base-specific contacts. The second approach tested a
structure-based strategy to design a chimeric domain composed of the Oct-1
homeodomain fused to two zinc fingers. It is useful to consider these efforts in the light
of related experiments conducted to change DNA-binding specificity in other systems.
The attempt to change the DNA-binding specificity of a transcription factor may
stem from several motives. These may include the desire to identify the residues in the
protein which contact DNA, the evaluation of the flexibility of a domain for recognizing
different sequences, and the development of proteins which will recognize a particular
desired sequence for practical application in biological research or gene therapy. Both
genetic and biochemical approaches have been fruitful (e.g. Youderian et al., 1983;
Wharton and Ptashne, 1985; Ebright et al., 1987; Tzamarias et al., 1992; Huang et al.,
1994). This section will discuss two examples. The first, the TATA-binding protein
(TBP) m3 mutant, is one of the best examples of the use of an altered-specificity variant
as a research tool. The second, the selection of zinc finger variants by phage display,
may be the most powerful method for the development of proteins with desired sequence
specificities.
T'BPm3
A transcription factor variant with a novel specificity is perhaps most useful in an
:in vivo context where the wild-type variant is ubiquitious and necessary for the viability
of the cell. The TATA-binding protein may represent the best example of an
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indispensable transcription factor that is present in any in vivo eukaryotic context. The
protein is necessary for transcription by polymerases I, II and III, and residues on the
surface of the protein mediate interactions with other general transcription factors, TATA
binding protein associated factors (TAFs), and sequence-specific transcription factors
(Hernandez, 1993). Strubin and Struhl (1992) used a genetic selection to isolate a variant
of TBP that could be manipulated in yeast without concern about cell viability. They
isolated a mutant, TBPm3, that would bind to the sequence TGTAAA, which is not
bound efficiently by the wild-type TBP. The activity of TBPm3 could be monitored on
an artificial promoter containing a TGTAAA TATA box, while the wild-type endogenous
TBP would remain in the background to support cell-viability but not interact with the
artificial reporter. The altered-specificity mutations in this yeast protein also worked in
the context of TBPs from other organisms, affording the opportunity to assay the
functional differences between TBPs from different species. Although human TBP could
not replace yeast TBP for cell viability, an altered-specificity human TBP was able to
support Pol II transcription in yeast and respond to the GCN4 activator. This observation
led to experiments that showed that human TBP is incompatible for transcription in yeast
at Pol I, Pol II, and TATA-less Pol II promoters (Cormack et al., 1994). These studies
allowed critical residues that differ between yeast and human TBPs to be mapped.
Altered-specificity TBPs have also been used in plant (Heard et al., 1993) and human
cells (Tansey et al., 1994). In the latter study, mutagenesis of TBP demonstrated that
many regions on the surface of the protein paticipate in the response to activators of Pol II
transcription. Finally, the altered-specificity yeast variant has been useful for
experiments suggesting that the association of TBP with the promoter can be a rate-
limiting step in the transcription initiation pathway in vivo, and that a sequence-specific
transcription factor can stimulate transcription by enhancing TBP association with the
TATA box (Klein and Struhl, 1994; Chatterjee and Struhl, 1995; Klages and Strubin,
1995).
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TBPm3 was isolated without knowledge of the structure of TBP and without a
firm idea of which residues in the protein mediated DNA-recognition. If such
information is available for a particular domain, an approach becomes feasible in which
the residues that contact DNA are randomized and a selection or screen is performed.
One of the systems that applies this strategy and promises to deliver proteins with many
applications involves the selection of zinc finger variants by phage display.
Selection of zinc finger variants by phage display
The phage display technology has offered the ability to select among up to a
billion variants of a DNA-binding domain for one that has a desired sequence specificity.
The essential feature of the system is that it allows a protein variant to be assayed in vitro
for binding activity while it is physically associated with the DNA that encodes it (Smith
and Scott, 1993). The domain being studied is fused to one of the proteins that is
incorporated into the coat of a filamentous phage. When the phage is assembled, the
DNA packaged into the phage will contain the gene for this fusion, either in the phage
genome or in a phagemid. Phage are isolated for binding activity on solid supports
containing the immobilized target DNA sequence, and the retained phage are eluted and
amplified by infection of E. coli.
Several laboratories have applied this sytem to C2H2-type zinc fingers (Rebar and
Pabo, 1994; Jamieson et al., 1994; Choo and Klug, 1994ab). Crystallographic analyses
have defined the structure of zinc finger domains, their arrangement when bound to
DNA, and the residues in the zinc finger which are responsible for base-specific
interactions in the major groove (Pavletich and Pabo, 1991, 1993, Fairall et al., 1993).
Using phage display, several studies have been able to select variants of the three finger
domain of Zif268 (Rebar and Pabo, 1994; Jamieson et al., 1994; Choo and Klug,
1994ab). Each of the three fingers in this domain recognizes a triplet of base pairs in the
9 base-pair binding site. In these experiments, one of the three fingers has been
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randomized in the context of the other wild-type fingers, and variants have been obtained
which bind to a wide variety of triplets of base-pairs.
The modularity of the zinc finger domain has offered the opportunity to
covalently link a set of three selected zinc fingers into a new composite domain. In this
manner, Choo et al. (1994) have developed a protein that binds in a sequence-specific
manner to a model target for therapeutic intervention, a BCR-ABL cDNA. The BCR-
ABL gene product encoded in the cDNA corresponds to that which is produced in acute
lymphoblastic leukemia as a result of a chromosomal translocation. In a model system,
the stable transfection of this BCR-ABL cDNA confers IL-3 independence on a murine
cell line in tissue culture. When this cell line was transiently transfected with a plasmid
encoding the designed protein, IL-3 dependence was restored. The designed factor
presumably inhibits transcription of the BCR-ABL cDNA by blocking elongation of
RNA polymerase, although this has not been proven. Although it relies on a model
system, this experiment highlights the potential therapeutic applications of proteins
designed to bind to specific sequences.
Among the different classes of DNA-binding domains, zinc fingers may possess
the widest repertoire for sequence recognition. Naturally occurring zinc fingers recognize
a wide variety of sequences, and crystallographic analyses demonstrate that zinc fingers
may dock to DNA in different ways (Pavletich and Pabo, 1993; Fairall et al., 1993).
Other DNA-binding domains may not be as adaptable to different binding sites. Several
families of transcription factors appear to have evolved to recognize a particular sequence
motif, such as the basic-helix-loop helix (CANNTG) (Murre and Baltimore, 1992) and
nuclear hormone receptor (AGNNCA, half site) (Evans, 1988) families.
The first attempt to develop an altered-specificity Oct-1 variant became an
investigation of the plasticity of the Oct-1 homeodomain for recognizing different base-
pairs in the major groove. The experiment, described in detail in Chapter 3, focused on
residues 47 and 51, and involved an approach of randomization followed by biochemical
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screening for binding activity. Valine 47 and asparagine 51 in the Oct-1 homeodomain
mediate interactions that are highly conserved in the homeodomain family of factors.
Valine 47 contacts the thymine that corresponds to the final residue in the TAAT core of
many homeodomain binding sites (TAATNN) (Klemm et al., 1994). Asparagine 51 is
one of the most highly conserved homeodomain residues and contacts the second adenine
(rAATNN)(Klemm et al., 1994).
The experiments demonstrated that among the many possible side-chain base
interactions between positions 47 and 51 and the third and fourth base-pairs in the TAAT
core, the wild-type combination of amino acids and base-pairs provided the interactions
with the highest affinity and specificity. A variant was obtained that could recognize a
sequence that the wild-type protein could not, but it could do so only with modest affinity
and specificity. These results suggested that the folding of the homeodomain and the
manner in which it docks to DNA constrain what residues can be used at positions 47 and
51 to interact specifically with DNA.
Several studies have shown that different residues can be introduced in the
homeodomain at position 50 to change specificity for residues 3' to the TAAT core
(TAATNN) (Hanes and Brent, 1989, 1991; Treisman et al., 1989; Percival-Smith et al.,
1990; Ades and Sauer, 1994). Within a particular domain, there may be two sets of
residues which contact DNA, those that are inalterable, and those that can be changed to
modulate specificity. Which set a particular residue may belong to will probably be
determined by the orientation of that side chain as it is presented to the DNA. This
orientation will determine what trajectories are possible for the presentation of functional
groups in the amino acid side chain to their targets on the base-pairs or sugar-phosphate
backbone. The position of the -carbon backbone of the domain from which the side
chain emanates as well as the adjacent space occupied by other residues in the protein are
key constraints. Furthermore, the residues that mediate sequence recognition may be
interdependent. A set of residues at the protein-DNA interface may directly interact to
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position each other for the presentation of a surface complimentary to the DNA. A
change in specificity may not be attainable through the manipulation of a residue that
may only function as part of a network of recognition (Pabo and Sauer, 1992).
These realizations led to the pursuit of methods for changing the DNA-binding
specificity of the Oct-1 homeodomain without introducing mutations at the protein-DNA
interface. The high DNA-binding affinity and specificity of the Oct-1 POU domain
derives from the cooperative recognition of the octamer site (5'-ATGCAAAT-3') by two
domains which appear to be structurally independent yet connected by a 24 residue
linker: the POU-specific domain (which recognizes ATGC) and the homeodomain (which
recognizes AAAT) (Klemm et al., 1994). When examined individually, each subdomain
demonstrates only modest affinity for its subsite. The configuration of the POU domain
suggested that the homeodomain might be targeted to a novel DNA sequence if it were
fused to a heterologous DNA-binding domain instead of the POU-specific domain. As
detailed in Chapter 4, this prediction was tested by the structure-based design of ZFHD 1,
a chimeric protein in which the Oct-1 homeodomain was fused to zinc fingers 1 and 2 of
Zif268. The designed protein was found to have sequence specificity distinct from that
of either the parental Oct-1 or Zif268 proteins. When fused to an activation domain,
ZFHD1 could activate reporter gene expression in vivo in a sequence-specific manner.
Thus, the affinity and specificity of the designed factor allowed it to recognize a sequence
in vivo which could not be recognized efficiently by Oct-i. ZFHD 1 could thus provide
an altered specificity Oct-i variant without requiring any mutations at the homeodomain-
DNA interface. The first test of the utility of this factor is described in Chapter 5. In
these experiments, ZFHD1 was used to form the C1 complex on a novel sequence which
was not efficiently recognized by Oct-1. This allowed the demonstration in vitro and in
vivo that the Oct-i homeodomain could provide all of the Oct-i mediated protein-protein
interactions necessary for recruitment of aTIF and C1 factors into a functional C1
complex.
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CHAPTER II
RECOGNITION OF THE SURFACE OF A HOMEODOMAIN PROTEIN
This chapter originally appeared in Genes & Development 6: 2047-2057 (1992).
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ABSTRACT
Homeodomain proteins exhibit distinct biological functions with specificities that
cannot be predicted by their sequence specificities for binding DNA. Recognition of the
surface of the Oct-1 POU-homeodomain provides a general model for the contribution of
selective protein-protein interactions to the functional specificity of the homeodomain
family of factors. The assembly of Oct-1 into a multiprotein complex on the Herpes
Simplex Virus a/IE enhancer is specified by the interactions of its homeodomain with
ancillary factors. This complex (C1 complex) is composed of the viral aTIF protein
(VP16), Oct-i, and one additional cellular component, the C1 factor. Variants of the Oct-i
POU-homeodomain were generated by site-directed mutagenesis which altered the residues
predicted to form the exposed surface of the domain-DNA complex. Proteins with single
amino acid substitutions on the surface of either helices 1 or 2 of the Oct-i POU-
homeodomain had decreased abilities to form the C1 complex. The behavior of these
mutants in a cooperative DNA-binding assay with aTIF suggested that the Oct-1 POU-
homeodomain is principally recognized by aTIF in the C1 complex. The preferential
recognition of Oct- over the closely related Oct-2 protein is critically influenced by a single
residue on the surface of helix 1 since the introduction of this residue into the Oct-2 POU-
homeodomain significantly enhanced its ability to form a C1 complex.
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INTRODUCTION
Homeodomain proteins comprise a broad family of regulatory factors which are
important determinants for morphogenesis, cell-type determination, and cell-type-specific
functions in a wide evolutionary range of organisms (for reviews see Affolter et al., 1990;
Gehring, 1987; Scott et al., 1989). The homeodomain motif consists of a DNA-binding
domain that contains three a-helices and the determination of the structures of three
homeodomain-DNA complexes has revealed a general conservation of domain folding and
DNA recognition among proteins with minimal amino acid sequence similarity (Kissinger
et al., 1990; Otting et al., 1990; Wolberger et al., 1991). Most characterized
homeodomains specifically recognize a DNA sequence containing a 5'-TAAT-3' core
(Laughon, 1991), but despite having similar DNA-binding specificities, individual
homedomain proteins confer extremely specific regulatory actions (for review see Hayashi
and Scott, 1990). Furthermore, several studies suggest that the functional specificity of
homeodomain proteins is largely determined by a minimal region containing the
homeodomain (Kuziora and McGinnis, 1989; Gibson et al., 1990; Malicki et al., 1990;
Mann and Hogness, 1990; McGinnis et al., 1990; Lin and McGinnis, 1992; Furukubo-
Tokunaga et al., 1992). For example, the replacement of the homeobox sequences of the
Deformed gene of Drosophila melanogaster with the homeobox sequences in the
Ultrabithorax gene targets regulation by the chimeric gene in vivo to those sites which are
normally controlled by Ultrabithorax. This change in specificity occurs even though the
DNA-recognition helices of these two homeodomains are essentially identical (Kuziora and
McGinnis, 1989; Lin and McGinnis, 1992). A critical question, therefore, concerns how
homeodomain regulatory specificity is determined.
One possible mechanism for the determination of the biological specificity of
homeodomains invokes interactions with other regulatory proteins. While a single
homeodomain may have the potential to bind to many target promoter sites, it may be
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specifically recruited into a functional complex at only a subset of those sites by selective
protein-protein interactions.
An excellent system for studying interactions between homeodomains and other
proteins involves the differing abilities of two highly homologous proteins, Oct- 1 and Oct-
2, to assemble into a multiprotein complex on the Herpes Simplex Virus aILE enhancer
element. This element (5'ATGCTAATGATATTCTTTGG3') is required for the
transcriptional regulation of the five viral a genes (Mackem and Roizman 1982a-c; Kristie
and Roizman, 1984; Gaffney et al., 1985; Bzik and Preston, 1986; for review, see
McKnight et al., 1986) and is recognized by a multiprotein complex (C1 complex) that
contains Oct-i, the viral factor aTIF (VP16, Vmw65, ICP25) (McKnight et al, 1987;
Preston et al, 1988; O'Hare and Goding, 1988; Gerster and Roeder, 1988; Stern et al.,
1989; Kristie et al., 1989), and at least one additional cellular factor, the C1 factor (Kristie
et al., 1989; Xiao and Capone, 1990). The 5' portion of the enhancer element consists of
a homolog of the consensus octamer site (5'-ATGCAAAT-3') and is specifically
recognized by the Oct-1 POU domain (Kristie and Sharp, 1990), which contains POU-
specific and POU-homeo subdomains characteristic of the POU domain subclass of
homeodomain factors (Herr et al., 1988). The remainder of the element is recognized by
aTIF, and possibly by components of the cellular C1 factor (Kristie and Sharp, 1990).
Initial analyses of the C1 complex suggested that most, if not all, of the Oct-1
determinants that mediate protein-protein interactions in the formation of the C1 complex
are contained in the POU-homeodomain of the protein (Kristie and Sharp, 1990).
However, despite a high degree of homology with Oct-1 in the region of the POU-
homeodomain, and an apparently equivalent ability to bind to the DNA element, Oct-2 had
a 100 fold lower potential to form a C1 complex (Kristie et al., 1989). Although
interactions between Oct-1 and aTIF have been demonstrated in the absence of the C1
factor (Kristie and Sharp, 1990; Stern and Herr, 1991), it remains unclear which
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component of the C1 complex is responsible for the selective recognition of the Oct-1
POU-homeodomain.
Site-directed mutagenesis has been used to determine which amino acids are
important for the recognition of the Oct-i POU-homeodomain in the formation of a C1
complex. The results indicate that residues on the surface of both putative helices 1 and 2
are important in the selective protein-protein interactions and that a single amino acid
substitution in helix 1 of the Oct-2 POU-homeodomain promotes significant interaction of
this protein with components of the C1 complex. Additionally, evidence is presented that
aTIF is the component of the C1 complex which is principally responsible for the
recognition of the Oct-i POU-homeodomain. This study demonstrates that individual
amino acid differences between highly related homeodomains can dictate functional
specificity through specific protein-protein interactions with regulatory factors.
RESULTS
Differing abilities of the Oct-1 and Oct-2 POU-homeodomains to participate
in C1 complex formation
The Oct-1 and Oct-2 POU-homeodomains were produced as Staphylococcus
protein A (PA) fusion proteins and compared in an electrophorectic mobility shift assay for
their potential to form the C1 complex (Figure 1). As previously observed (Kristie and
Sharp, 1990), the Oct-1 POU-homeodomain binds to the HSVaO probe, which contains
the a/IE element, cooperatively as a homodimer (lane 3), and forms the multiprotein C1
complex upon addition of aTIF (PA-aTIF) and a chromatographic fraction of HeLa cell
nuclear extract containing the C1 factor (lane 4). The Oct-2 POU-homeodomain, however,
generates a complex on the a/IE element with the expected mobility of a monomeric
protein-DNA complex (lane 5), and does not form a C1 complex in the presence of acTIF
and the C1 factor (lane 6). Thus, the Oct-1 and Oct-2 POU-homeodomains differ in both
the potential to dimerize on the cA/IE element and in the ability to interact with the aTIF and
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Figure 1. Comparison of Oct-1 and Oct-2 POU-homeodomains in the assembly of a C1
complex. DNA-protein binding reactions were done as described in Materials and
Methods. The probe DNA, HSVaO, contains the aIE element from -168 to -142 of the
o promoter. Protein A fusion proteins containing the Oct-1 POU domain (100 pg), the
Oct-i POU-homeodomain (100 ng), or the Oct-2 POU-homeodomain (100 ng) were
incubated in the absence (-) or presence (+) of 15 ng PA-aTIF and 1gl of a
chromatographic fraction containing the HeLa cell C1 factor as indicated. The positions of
the multiprotein C1 complex as well as the monomeric and homodimeric Oct- 1- or Oct-2-
DNA complexes are indicated with arrows.
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C1 factors. As will be shown later, the ability to bind as a dimer is not related to the
potential to form a C1 complex. Furthermore, both proteins bind as monomers to a probe
containing a consensus octamer site with comparable affinity (data not shown). Clearly,
the POU-homeodomains of Oct-1 and Oct-2 contain determinants which mediate their
discrimination by aTIF, the C1 factor, or both.
Residues in the Oct-i POU homeodomain involved in C1 complex
formation
Amino acid residues in the Oct-1 POU-homeodomain which are most likely to
mediate specific protein-protein interactions would be expected to be located on the
physically available surface of the DNA-bound domain and to be divergent among
members of the POU domain family of factors. A model of the Oct-i POU-homeodomain
(Figure 5) was generated by aligning its sequence with that of the engrailed homeodomain
and positioning its amino acids based upon the crystal structure of the engrailed
homeodomain-DNA complex (Kissinger et al., 1990). A comparison of the POU-
homeodomain amino acid sequences among representatives of the different classes (He et
al., 1989) of POU domain proteins is depicted in Figure 2A. The regions that contain the
most highly conserved residues within this family are boxed. The amino acid sequence of
the engrailed homeodomain is listed for comparison, and the positions of residues which
have been noted in the structural studies to be involved in packing of the hydrophobic core
or in homeodomain-DNA interactions are indicated. Most of these positions lie within
regions that are highly conserved among POU-domain factors, as would be expected if
homeodomain structure and DNA recognition is generally conserved. The unboxed or
divergent amino acids could be responsible for factor-specific protein-protein interactions
that contribute to the functional specificities of these proteins. Helical wheel
representations (Figure 2B) of helices 1 and 2 of the Oct-i POU-homeodomain predict that
the divergent residues, including those that differ between Oct-1 and Oct-2, comprise the
surface expected to remain physically accessible upon DNA binding.
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Figure 2. (A) Comparison of POU-homeodomain amino acid sequences among several
POU-domain factors. Amino acids which are highly conserved in the POU-homeodomain
of proteins representing the different subclasses (He et al., 1989) of POU-domain factors
are boxed. The seven amino acids which differ between Oct- and Oct-2 are indicated (-).
The positions occupied by residues which have been noted in structural studies to contact
DNA (dark rectangles) or to participate in interactions within the core of the domain (dark
circles), as well as those which are highly conserved among all homeodomains (open
circles) are indicated below the sequence of the engrailed homeodomain as adapted from
Laughton, 1991. For ease of comparison with other homeodomain proteins, the amino
acids are numbered according to the scheme of Qian et al., 1989. The POU-homeodomain
amino acid sequences have been previously compiled by Rosenfeld, 1991. (B) Helical
wheel representations of helices 1 and 2 of the Oct- POU-homeodomain. The divergent
amino acids are indicated in bold type while the conserved amino acids are in outline type.
The amino acids which differ between Oct-i and Oct-2 are underlined. The dashed line
divides the helices into two halves, the lower of which is predicted to pack against helix 3
and face the DNA in a protein-DNA complex.
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Thus, both the modeled structure of the Oct-i POU-homeodomain and the sequence
comparison of several POU domain proteins define a common set of amino acids which are
likely to be responsible for protein-protein interactions, and which were therefore targeted
for site-directed mutagenesis. The substitution of these amino acids would not be expected
to disrupt either the domain's structure or its ability to bind DNA. Since the amino acids
that are different between Oct- and Oct-2 in the region of the POU-homeodomain must
contribute to the differential ability of these proteins to interact with components of the C1
complex, the appropriate Oct-i residues were substituted with the corresponding Oct-2
residues. Other amino acids in the selected set were mutated so as to remove potentially
important functional groups or to alter the character of a particular residue (i.e from positive
to negative, hydrophobic to polar, and vice versa). All of the constructed variants of the
Oct-1 POU-homeodomain were expressed in E. coli as PA fusions and purified by
chromatography on IgG sepharose. In order to test their structural integrity and their
capacity to bind DNA, all mutants were titrated into reactions containing an octamer
consensus site probe. All mutants bound with affinities that were comparable to that of the
wild type protein (data not shown).
Each mutant polypeptide was tested for the ability to bind to the alE element and to
interact with the aTIF and C1 factors in a C1 complex assembly assay. The proteins were
titrated into reactions containing the a/IE element and were found to cooperatively form
homodimers in a manner similar or identical to that of the wild type protein (data not
shown). Several amino acid substitutions significantly reduced the ability of the Oct-1
]POU-homeodomain to form a C1 complex. As illustrated in Figure 3, mutant proteins
were incubated with aTIF and a chromatographic fraction of HeLa cell nuclear extract
containing the C1 factor and assayed in an electrophoretic mobility shift assay. For
quantitative analysis, each protein was assayed for its ability to form a C1 complex at
identical DNA binding activity (Table 1). Substitution of lysine 18 with glutamic acid
(K18E) (Figure 3, lane 8), serine 19 with cysteine (S19C) (lane 10), or glutamic acid 22
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Figure 3. Effects of amino acid substitutions in helices 1 and 2 of the Oct-i POU-
homeodomain on the formation of a C1 complex. Wild type (WT) (50 ng) and mutant PA-
Oct-l-POU-homeodomain fusion proteins (30-80 ng) were incubated in DNA-protein
binding reactions in the absence (-) or presence (+) of 15 ng PA-aTIF and lgl of a
chromatographic fraction containing the HeLa cell C1 factor as indicated. The positions of
the C1 and homodimeric POU-homeodomain-DNA complexes are indicated with horizontal
arrows. Vertical arrows indicate the Oct-i 1 POU-homeodomain variants in which the Oct-i
residues which differ from those of Oct-2 in the POU-homeodomain have been substituted
with the corresponding Oct-2 amino acids.
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TABLE 1. Phenotypes associated with amino acid substitutions in the Oct-l POU-
homeodomain.
SUBSTITUTION
Nll to Gll
Nll to All
I12 to V12
I12 to G12
V14 to G14
V14 to F14
A15 to G15
K18 to E18
S19 to G19
S19 to C19
L21 to G21
E22 to A22
ABILITY TO ABILITY TO
FORM C1 (%WT)a INTERACT WITH acTIF
123 +
108 +
109 - +
92 +
114 +
89 +
75 +
13
81 +
13
99 +
16
E29 to Q29 101 +
E30 to Q30 5
T32M33 to L32L33 77 +/-
T32M33 to V32V33 34
T32M33 to L32V33 39
D36 to E36 95 +
Helix 2 Q37 to E37 108 +
Q37 to A37 105 +
N39 to H39 98 +
N39 to D39 145 +
N39 to Y39 113 +
T32M33D36 to L32L33E36 68 +/-
S28T32M33 to L28L32L33 73 +/-
aPA-Oct-l1 POU-homeodomain fusion proteins were incubated in DNA-protein binding
reactions with subsaturating amounts of PA-aTIF and C1 factor as described in Materials
and Methods and in the legend to Figure 3. The amount of C1 complex formed with each
mutant protein was compared to that formed with the wild type at equivalent DNA binding
activity in reactions in which 0.1-1.0% of the probe was bound by POU-homeodomain
homodimer. In all cases, the concentration of mutant protein that was required to achieve
equivalent DNA binding to that of the wild-type protein did not vary by more than twofold
of the wild-type protein concentration. The numbers correspond to the average of at least
three experiments for each mutant. The substitutions are grouped according to location in
helices 1 and 2. Substitutions that were made in the intervening loop reduced the apparent
DNA binding affinity of the domain and were therefore not pursued.
bPA-Oct-l 1 POU-homeodomain fusion proteins were incubated in DNA-protein binding and
IJV-crosslinking reactions as described in Materials and Methods and in the legend to
Figure 4. + indicates that the Oct- POU-homeodomain variant stimulated the efficiency of
IJV crosslinking of PA-aTIF to DNA by 4-6 fold or to a level equivalent to that observed
with the wild type protein. +/-indicates 2-3 fold stimulation while - indicates <1.5 fold
stimulation.
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Helix 1
-
with alanine (E22A) (lane 14) in helix 1, or glutamic acid 30 with glutamine (E30Q) (lane
18) in helix 2 reduced the capacity of the Oct- POU-homeodomain to form a C1 complex
to that of 13%, 13%, 16% and 5% of wild type, respectively. In contrast to the
substitution of serine 19 with cysteine, substitution of serine 19 with glycine (S19G)
resulted in a protein with only a mildly reduced ability (81% wild type) to form a C1
complex (lane 12). Oct-i and Oct-2 differ in the POU-homeodomain at positions 12, 14,
22, 32, 33, 36, and 39. Of these, only substitution of the Oct-1 residue at position 22 with
the corresponding Oct-2 residue dramatically affected the protein's ability to form a C1
complex (Figure 3, compare lanes 4, 6, 14, 20, 22, and 24, see Table 1). Stern et al.
(1989) previously demonstrated that the simultaneous substitution of residues threonine 32,
methionine 33, and aspartic acid 36 in the Oct-1 helix 2 with the corresponding residues
from the Oct-2 POU-homeodomain reduced the efficiency of C1 complex formation. In
this analysis the same combination of substitutions (T32L, M32L, D36E) had a relatively
mild effect (68% wild type) (Figure 3, lane 26) compared to that which resulted from the
aforementioned individual amino acid substitutions.
It is clear from these data that residues in both helices 1 and 2 of the Oct-1 POU-
homeodomain mediate protein-protein interactions which are required for the efficient
assembly of the C1 complex. Among those amino acids which, when substituted, result in
a polypeptide which is significantly disabled with respect to the formation of a C1 complex
are those which are likely to be specifically and directly involved in the recognition of the
Oct-1 POU-homeodomain by the aTIF and C1 factors.
Interaction of Oct-1 POU-homeodomain variants with aTIF
The reduced ability of a mutant Oct- POU-homeodomain protein to participate in
the formation of a C1 complex could be due to its diminished capacity to interact with
(xTIF, the C1 factor, or both. Although an Oct-I:aTIF:DNA intermediate complex is not
readily detected in a native gel electrophoretic mobility shift assay, the cooperative DNA
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binding interaction between the Oct-i POU-homeodomain and aTIF in the absence of the
C1 factor can be detected in a UV-induced crosslinking assay (Kristie and Sharp, 1990).
Therefore, this assay was used to address whether the panel of mutant proteins could
interact directly with aTIF. As illustrated in Figure 4, the wild type POU-homeodomain
stimulated the efficiency of UV-crosslinking of aTIF to the c/IE element by 4-5 fold as
compared to reactions containing only the aTIF protein (compare lanes 2 and 3).
Interestingly, each of the mutant proteins which contained amino acid substitutions that
significantly reduced the ability of the protein to form a C1 complex also failed to stimulate
the crosslinking of aTIF to DNA (lanes 6, 7, 9, and 11). The mutant proteins which
exhibited relatively milder phenotypes with respect to their assembly into C1 complexes
also exhibited diminished capacities to stimulate the cooperative DNA-binding of aTIF
(Table 1). Conversely, those Oct-i POU-homeodomain variants which exhibited nearly
wild type phenotypes in a C1 complex formation assay also retained the ability to stimulate
the crosslinking of aTIF (lanes 4, 5, 8, 10, 12, and 13, for example, Table 1). Thus, the
phenotype exhibited by all mutants which were deficient in the assembly of a C1 complex
can be accounted for by their decreased abilities to interact specifically with the viral aTIF
factor.
A single amino acid substitution in the Oct-2 POU-homeodomain confers
the ability to efficiently participate in the formation of a C1 complex and to
stimulate the cooperative DNA-binding of aTIF
Figure 5 depicts the surface of the Oct-1 POU-homeodomain which should be
accessible for protein-protein interactions. The arrows denote residues 18, 19, 22, and 30,
which, when substituted individually, resulted in mutant proteins with significantly reduced
potential to form the C1 complex and to cooperatively interact with aTIF. These residues
are thus expected to be involved in the critical interactions of the Oct-i POU-homeodomain
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Figure 4. Cooperative interactions of aTIF with variants of the Oct-1 POU-
homeodomain. DNA-protein binding and UV-crosslinking reactions were done as
described in Materials and Methods. The reactions contained 1100 ng SDS-PAGE purified
PA-aTIF and 500 ng wild type (WT) or mutant PA-Oct-1 POU-homeodomain fusion
proteins as indicated. The positions of the PA-aTIF (74 kD) and PA-Oct-1 POU-
homeodomain (38 kD) proteins are indicated with arrows. The 27 kD species is a
degradation product of the PA-Oct-l POU homeodomain proteins. The bands at 17 kD and
36 kD are present in control reactions in the absence of any PA fusion protein and are thus
likely to be incompletely digested DNA. The migrations of 14C protein molecular weight
markers are indicated at the right.
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Figure 5. The surface of the Oct-1 POU-homeodomain which is specifically recognized
in the assembly of the C1 complex. The Oct-i POU-homeodomain was modeled according
to the crystal structure of the engrailed homeodomain-DNA complex (Kissinger et al.,
1990). The displayed amino acids are expected to occupy positions in helices 1, 2, and the
intervening loop which are on the surface of the domain that is opposite to the DNA
binding surface. The residues which, when substituted, resulted in the most pronounced
reductions in the ability to form the C1 complex and to stimulate the cooperative DNA
binding of aTIF are indicated with arrows. The amino acids which differ between Oct-i
and Oct-2 in the POU-homeodomian are boxed.
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with aTIF in the assembly of a C1 complex. The amino acids which differ between the
Oct-1 and Oct-2 POU-homeodomains are indicated by boxes.
Of the seven amino acid differences between Oct-i and Oct-2 in the POU-
homeodomain, substitution of the glutamic acid at position 22 in Oct-i for the
corresponding alanine in Oct-2 produced a protein which displayed the most significant
phenotype. This suggested that the amino acid at this position would not only be a key
determinant for the recognition of Oct-i in the formation of a C1 complex but also one that
might account for the significantly lower affinity of the Oct-2 POU-homeodomain for
components of the C1 complex. Therefore, a variant of the Oct-2 POU-homeodomain was
produced which contained a substitution of the Oct-2 alanine at position 22 with the Oct-1
glutamic acid. As shown in Figure 6A, this single substitution now confers upon the Oct-2
POU-homeodomain the ability to efficiently interact with components of the C1 complex
(compare lanes 2 and 4). This Oct-2 variant bound to the a/IE element as a monomeric
protein with an affinity that was comparable to that of the wild type Oct-2 POU-
homeodomain (lanes 1 and 3, data not shown). Based on the results obtained with the Oct-
1 variants, it was expected that the enhanced capacity of this protein to form a C1 complex
would be concomitant with an increased ability to directly interact with aTIF. As shown in
Figure 6B, the Oct-2 POU-homeodomain variant does, in fact, have an increased ability to
stimulate the binding of aTIF to DNA in the UV-induced crosslinking assay as compared
to the wild type Oct-2 POU-homeodomain protein (compare lanes 2 and 3).
DISCUSSION
Although it is clear that homeodomain proteins are critical for many highly regulated
processes, the mechanisms by which these proteins act with exquisite functional specificity
have been largely undefined. The functions of homeodomain proteins have been most
extensively investigated in Drosophila morphogenesis, in which the regulatory specificity
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Figure 6. The substitution of alanine 22 with glutamic acid in the Oct-2 POU-
homeodomain enhances the ability of the protein to form a C1 complex and interact with
aTIF. (A) The wild type (WT) PA-Oct-2 POU-homeodomain (50 ng) or a mutant
containing the substitution of alanine 22 with glutamic acid (A22E) (50 ng) were incubated
in DNA-protein binding reactions in the absence (-) or presence(+) of 15 ng PA-aTIF and
ipi1 of a chromatographic fraction containing the HeLa cell C1 factor as indicated. The
positions of the C1 and monomeric Oct-2 POU-homeodomain-DNA complexes are
indicated with arrows. (B) DNA-protein binding and UV-crosslinking reactions were done
using 930 ng SDS PAGE-purified PA-aTIF, alone or in the presence of 500 ng of either
the wild type (WT) PA-Oct-2 POU homeodomain or the A22E mutant. The positions of
the PA-aTIF (74 kD) and PA-Oct-2 POU-homeodomain (38 kD) are indicated with
arrows. The migrations of 14C protein molecular weight markers are indicated at the right.
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of several proteins has been mapped to a minimal region containing the homeodomain
(Kuziora and McGinnis, 1989; Gibson et al., 1990; Malicki et al., 1990; Mann and
Hogness, 1990; McGinnis et al., 1990; Lin and McGinnis, 1992; Furukubo-Tokunaga et
al., 1992). This specificity cannot solely be explained by the DNA-binding properties of
these homeodomains since proteins with distinct biological actions exhibit extremely similar
DNA sequence specificities. We propose that the biological specificity contained in the
homeodomain can be primarily determined by the recognition of the surface of the DNA-
bound domain by other proteins. This is clearly the mechanism by which Oct- is
selectively assembled into the regulatory C1 complex on the a/immediate early enhancer of
the Herpes Simplex Virus. The recognition of Oct-1 is mediated principally by specific
interactions between the viral aTIF factor and amino acid residues on the surface of helices
1 and 2 of the Oct- 1 POU-homeodomain.
Amino acid residues in helix 1 and helix 2 of the Oct-1 POU-homeodomain
are critical for the assembly of the C1 complex
A panel of variants of the Oct-i POU-homeodomain was generated by site-directed
mutagenesis. In order to preserve the Oct-1 POU-homeodomain's structure and its ability
to bind DNA, the mutagenesis was limited to those amino acids which are divergent and
which are predicted to occupy positions on the surface of the domain. In most cases, the
character of an individual side chain residue was radically changed by the substitution, and
therefore a mutation which did not result in a dramatic phenotype indicates that the wild
type residue at that position is unlikely to mediate a critical interaction. Conversely, a
mutation which did result in a pronounced phenotype indicates that the wild type residue is
either directly interacting with components of the C1 complex or is sterically constrained in
the assembled complex. Specifically, the individual substitution of lysine 18, serine 19,
glutamic acid 22, and glutamic acid 30 resulted in the most dramatic reductions in the ability
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of the Oct-i POU-homeodomain to participate in the formation of a C1 complex. Although
lysine 18 may be specifically recognized in the C1 complex, the phenotype may also result
from a charge or steric incompatibility of the glutamic acid introduced at that position.
Serine 19 is unlikely to mediate a direct, specific interaction since only mild effects were
observed upon substitution of this residue with glycine. However, a more dramatic
phenotype resulted from the substitution of this residue with cysteine, which represents the
replacement of a hydroxyl group with a sulfhydryl group. This suggests that the side chain
of this residue is sterically constrained in the assembled complex. The result of the
replacement of glutamic acid 30 with glutamine indicates that this residue is in intimate
proximity to and may, in fact, mediate a direct contact with components of the C1 complex.
Finally, it is likely that glutamic acid 22 is specifically recognized in the C1 complex via a
direct interaction since the removal of much of its side chain (substitution with alanine)
resulted in a significant phenotype. More significantly, the replacement of alanine with
glutamic acid at position 22 in the Oct-2 POU-homeodomain resulted in a variant with a
dramatically enhanced ability to form a C1 complex.
Recognition of the Oct-1 POU-homeodomain by aTIF
Each amino acid substitution which compromised the formation of the C1 complex
also reduced the ability of the Oct-1 POU-homeodomain to cooperatively stimulate the
binding of aTIF to DNA, indicating that the surface of the Oct-i POU-homeodomain is
principally recognized by the viral aTIF protein. To date, the- specific role of the C1 factor
in the stabilization of the C1 complex is unclear. This multicomponent factor binds to
aTIF in the absence of DNA or Oct- (Kristie and Sharp, 1990). A related activity is also
present in insect cells (Kristie et al., 1989), suggesting that the C1 factor is evolutionarily
conserved.
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The importance of glutamic acid 22 in the Oct-1 POU-homeodomain
Stem et al. (1989) described a qualitative loss of the ability of the full Oct-i protein
to form a C1 complex when residues at positions 32, 33, and 36 in helix 2 were
simultaneously substituted with the corresponding Oct-2 residues. The interpretation of this
data was that helix 2 of the Oct-i POU-homeodomain contained the critical determinants for
the assembly of Oct-i into a C1 complex. In contrast, the equivalent construct in this
analysis (T32L, M33L, D36E) exhibited only a mildly reduced ability (68 % wild type) to
form the C1 complex. Other mutants which contained simultaneous substitutions of
threonine 32 and methionine 33 had- intermediate phenotypes in the C1 complex formation
assay (34-77%wild type) and exhibited diminished abilities to stimulate the crosslinking of
(xTIF to DNA. However, the data presented here suggest that the most significant
individual determinant for the discrimination between Oct-i 1 and Oct-2 lies not in helix 2 but
in helix 1 at position 22. Substitution of the glutamic acid in Oct- 1 for the alanine in Oct-2
produced an Oct-i variant with a dramatically reduced ability to form a C1 complex and to
interact with aTIF. The reciprocal exchange (Oct-2 A22E) resulted in an Oct-2 POU-
homeodomain protein with a significantly enhanced ability to form a C1 complex and to
directly interact with aTIF. This strongly implicates the glutamic acid at position 22 as a
critical determinant for the selective recognition of Oct-i in the formation of the C1
complex.
The cooperative binding of the Oct-1 POU-homeodomain
In contrast to the intact Oct-i POU domain, the Oct-i POU-homeodomain can bind
the aIE element cooperatively as a homodimer (discussed in Kristie and Sharp, 1990).
The difference in the abilities of the isolated Oct-i and Oct-2 POU-homeodomains to
cooperatively form a homodimer on the a/IE element was surprising but it is unlikely to be
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related to the proteins' respective capacities to interact with other components in the
formation of a C1 complex. The amino acid substitutions in Oct-1 which diminished its
ability to form a C1 complex did not affect its potential to form a homodimer on the acIE
element. Conversely, the mutation in Oct-2 (A22E) which enhanced its capacity to form a
C1 complex did not confer the ability to form a homodimer. The differences which account
for the different potentials of the Oct-l and Oct-2 POU-homeodomains to cooperatively
homodimerize are presently under investigation. The homodimerization of the Oct-1
protein may reflect unique capabilities of this protein for homeodomain-homeodomain
interactions with other proteins. Consistent with this notion, Voss et al. (1991) have
demonstrated that Oct-1 and the pituitary-specific POU domain factor Pit-1 bind as a
heterodimer to elements in the rat prolactin promoter and that the two proteins also associate
in solution via an interaction mediated, in part, by the POU-homeodomain of Pit-1. Of
note, Treacy et al. (1992) have described the interesting regulatory consequences of the
contrasting abilities of the Drosophila I-POU and Twin of I-POU proteins to interact with
the Cfl-a protein via POU-homedomain-POU-homeodomain interactions.
The interaction of Oct-1 and aTIF provides a model for the determination
of homeodomain functional specificity by protein-protein interactions
It is possible that the POU-homeodomains of Oct-i and Oct-2 are recognized by
cellular factors which are analogous to aTIF and which serve to modulate their functional
specificities. The existence of such factors would explain how the octamer element, which
is recognized by both of these proteins, is important for the regulation of a wide variety of
disparately controlled genes including the constitutively expressed snRNA genes (Ares et
al., 1987; Bark et al., 1987; Carbon et al., 1987; Murphy et al., 1987), the cell-cycle-
specifically expressed histone H2B gene (Sive et al., 1986; Fletcher et al., 1987; LaBella et
al., 1988), and the tissue-specifically expressed interleukin-2 (Ullman et al., 1991) and
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immunoglobulin genes (Mizushima-Sugano and Roeder 1986; Staudt et al., 1986;
Scheidereit et al., 1987; Wirth et al., 1987; LeBowitz et al., 1988; Muller et al., 1988;
Gerster et al., 1987).
It is likely that the recognition of the homedomain surface by other proteins is a
common mechanism by which the regulatory specificities of this family of factors are
determined. In Drosophila, where the developmental regulatory potential of a particular
factor can be readily assayed, minimal amino acid differences between two homeodomains
can determine the distinct biological actions of the proteins (Lin and McGinnis, 1992). The
observation that this biological specificity may not be related to DNA-binding specificity is
readily explained by a model based upon the recognition of the surface of the homeodomain
such as that proposed here for the Oct-1 POU-homeodomain. In this system, the four
critical residues for C1 complex formation are clustered in the C-terminal half of helix 1 and
the N-terminal third of helix 2. Therefore, this surface of the Oct-i POU-homeodomain
must be exposed to components of the C1 complex when the Oct-i protein binds DNA in
vivo. This spatial architecture is probably a general feature of homeodomain proteins: the
surface of the domain is exposed in the protein-DNA complex, providing a target for
regulatory proteins which contribute to homeodomain functional specificity.
MATERIALS AND METHODS
Mutagenesis and production of PA fusion proteins. Constructs encoding the S.
aureus protein A fusion proteins which contained the Oct- POU domain [amino acids 270-
441, (Sturm et al., 1988)] and aTIF [amino acids 1-412, (Pellett et al., 1985)] have been
described (Kristie and Sharp, 1990). Plasmid pOlHSS was constructed by cloning the
DNA fragment encoding the Oct-1 POU-homeodomain (amino acids 368-441) into the
vector pBS(+) (Stratagene) using the E. coli TG1 strain. The resultant transformant was
grown with R408 Helper Phage (Stratagene) at 370C for 18 hr. Single stranded DNA was
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isolated from the culture supernatant following the addition of 0.25 volume 20% PEG
(8000)/3.5M NH4Ac, incubation at 4°C for 30 minutes, and centrifugation at 10000 g for
20 minutes. The single stranded DNA pellet was extracted five times with
phenol/chloroform [1 vol: lvol], precipitated with ethanol and resuspended for use as a
substrate for mutagenesis. Mutagenesis was performed using the Oligonucleotide-directed
in-vitro mutagenesis system version 2 (Amersham) according to the manufacturers
instructions. Oligonucleotides used for the mutagenesis were from 20 to 30 nucleotides
long and contained approximately 10 nucleotides on each side of the mutation-specific
base(s). The products of the mutagenesis reactions were screened by dideoxynucleotide
sequencing. The fragments which contained the desired mutations were isolated and
cloned into pRIT2T(Pharmacia) so as to generate in frame fusions with the PA gene.
Plasmid pO2HWT was constructed by cloning the DNA fragment encoding the Oct-2
POU-homeodomain [amino acids 286-356, (Clerc et al., 1988)] into pRIT2T so as to
generate an in frame fusion with the PA gene. pO2HA317E, a construct encoding the Oct-
2 POU-homeodomain mutant (alanine 317 to glutamic acid) was generated by making a
base substitution via Recombinant PCR (Higuchi, 1990). The sequences of both Oct-2
constructs were verified by dideoxynucleotide sequencing.
Protein A fusion proteins were expressed in E. coli N4830 strain and were purified by
affinity chromatography on IgG-Sepharose (Pharmacia) as described (Kristie and Sharp,
;1990). The concentration and purity of each PA fusion protein were determined by
densitometric analysis of Coomassie-staining SDS-PAGE-resolved proteins. The fusion
proteins were judged to be 30-90% pure.
Electrophoretic Mobility Shift Assays. The HSVaO probe (a/IE element: 5'-
GTGCATGCTAATGATATTCTTTGGGG-3') used in the C1 complex formation assays
has been described (Kristie and Sharp, 1990). DNA-protein binding reactions contained
0.4-0.8 ng DNA probe, 300 ng poly[d(I-C)]/poly[d(I-C)], 10mM Hepes pH 7.9, 0.5 mM
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E]DTA, 30-90 mM KCl, 0.75 mM DTT, 4% Ficoll 400, 300 gg/ml bovine serum albumin,
and the appropriate purified proteins or chromatographic fraction in a total volume of 10 gl.
Reactions were incubated at 300C for 30 minutes and were resolved in 4% nondenaturing
polyacrylamide gels using 0.5x Tris-glycine electrophoresis buffer as described (Fried and
Crothers, 1981; Garner and Revzin, 1981). Chromatographic fractions which contained the
Cl1 factor were prepared by fractionation of a nuclear extract of HeLa cells (Dignam et al.,
1983). The extract was applied to a Mono S FPLC column in buffer A +100 mM KCl [40
mM HEPES pH 7.9/0.5 mM EDTA/0.5 mM D1T/20% (vol/vol) glycerol]. The column
was washed with 10 column volumes of buffer A + 100 mM KCl, and the adsorbed
proteins were eluted in buffer A with a linear gradient of 100-700 mM KC1. Fractions
which contained the C1 factor activity were applied to a Mono Q FPLC column in buffer A
+ 50 mM KC1. The column was washed with 10 column volumes of buffer A + 50 mM
KCI, and the adsorbed proteins were eluted in buffer A with a linear gradient of 50-700
mM KCl. The fractions which contained the C1 factor activity were combined and aliqouts
were incubated with potato acid phosphatase (SIGMA) for 15 minutes at 250C prior to
addition to protein-DNA binding reactions. In order to compare DNA binding affinities,
wild type and mutant PA-POU-homeodomain proteins were titrated into DNA-protein
binding reactions which were performed under the conditions described above using a
probe containing a consensus octamer site (5'ATGCAAAT3') (Kristie and Sharp, 1990),
30 ng poly[d(I-C)]/poly[d(I-C)], and between 5 and 500 ng of octamer binding protein.
T'he protein-DNA complexes and the free DNA were quantitated after electrophoresis using
a phosphorimager (Molecular Dynamics) with ImageQuant 3.0 and 3.15 software.
UV-induced crosslinking reactions. Body labeled DNA probes were prepared as
previously described (Kristie and Sharp, 1990). The DNA-protein binding reactions were
performed under the conditions described above and contained 40-150 ng poly[d(I-
C)]/poly[d(I-C)], 200-500 ng PA-POU-homeodomain protein, and 200-1100 ng PA-
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{aTIF. Reactions were incubated at 300C for 30 minutes and were irradiated with a
Fotodyne UV lamp (254nm) at 3000 gW/cm 2 in a 150C water bath. The reactions were
brought to 7.5 mM CaC12 and digested with 10 fgg DNase 1 and 5 units micrococcal
nuclease for 30 minutes at 370C. The digested products were resolved in an 11% SDS-
denaturing gel and transferred to nitrocellulose in the presence of 0.1% SDS. The PA-aTIF
used in these reactions was purified by preparative SDS-PAGE as described (Kristie and
Sharp, 1990). The amount of crosslinking of aTIF to DNA was quantitated using a
phosphorimager (Molecular Dynamics) with ImageQuant 3.15 software.
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CHAPTER III
HOMEODOMAIN DETERMINANTS OF MAJOR GROOVE RECOGNITION
This chapter originally appeared in Biochemistry 33: 10851-10858 (1994).
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ABSTRACT
The homeodomain is a highly conserved structural module that binds DNA and
participates in protein-protein interactions. Most homeodomains contain residues at
positions 47 and 51 which mediate recognition of a TAAT core binding sequence in the
major groove. The constraints imposed on the identity of these residues by
homeodomain structure and DNA-docking have been examined in the context of the
POU domain of the Oct-1 transcription factor. A bacterial library, in which POU-
homeodomain residues 47 and 51 have been randomized, was probed on nitrocellulose
filters for the binding of DNA fragments containing the consensus octamer sequence.
The residues which provide for the highest affinity interaction with the octamer
consensus sequence, and the greatest specificity, are the highly conserved wild-type
residues valine 47 and asparagine 51. Interestingly, a class of variants containing
arginine at position 51 was also detected in the screen and found to have moderate
affinity for the consensus sequence but reduced specificity compared to the wild-type
protein. A single variant containing arginine at both positions 47 and 51 was detected
when the library was probed with fragments containing nucleotide substitutions at
positions expected to be contacted by residues 47 and 51. This variant was used to alter
the DNA-binding specificity of a transcriptional regulatory complex which depends upon
Oct-1 for DNA recognition. These findings suggest that homeodomain structure and
DNA-docking constrain the versatility of the domain in that only a limited set of amino
acid determinants can endow the domain with specific, high affinity DNA binding.
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INTRODUCTION
The homeodomain is a structural module that determines the specificity of action
of a wide variety of transcription factors. This specificity is conferred by both its DNA-
binding surface as well as by surfaces that are targets for protein-protein interactions with
other transcriptional regulators. Structural analyses of homeodomain-DNA complexes
have revealed a highly conserved structure and mode of docking DNA (Kissinger et al.,
1990; Otting et al., 1990; Wolberger et al., 1991; Klemm et al., 1994). These studies
have complemented extensive biochemical and genetic experiments addressing the
interaction of the homeodomain with its conserved 5'-TAATNN-3' binding sequence
(Laughon, 1991). The homeodomain is composed of an N-terminal arm which makes
contacts with bases (5'-TAATNN-3') in the minor groove of DNA, and three a helices,
the third of which makes base contacts in the major groove (5'-TAATNN-3'). For several
homeodomains, specificity for nucleotides 3' to the TAAT core is determined by residue
50 in helix 3 (Hanes and Brent, 1989, 1991; Treisman et al., 1989; Percival-Smith et al.,
1990). Residues that contact the sugar-phosphate backbone are distributed throughout
the domain.
The highly conserved nature of homeodomain-DNA interactions raises the issue
of how different homeodomain proteins can exert specific regulatory effects, especially
when functional specificity maps to the homeodomain itself (Hayashi & Scott, 1990).
The observation that different homeodomains can determine dramatically different
biological actions despite little or no difference in DNA-binding specificity has led to the
description of mechanisms of specificity other than that provided by monomeric DNA-
binding. These involve homo- and hetero-dimerization of homeodomains and the
cooperative interaction of the homeodomain with other regulatory proteins (Smith &
Johnson, 1992; Pomerantz et al., 1992; Lai et al., 1992; Vershon & Johnson, 1993;
Wilson, D. et al., 1993 ).
80
The limited variation in the specificity of homeodomains for a TAAT core
binding site emphasizes the question of how the highly conserved tertiary structure of the
domain constrains its DNA-binding specificity for this core sequence. Most of the amino
acid determinants in the homeodomain that form specific contacts with bases in the
TAAT core are highly conserved among homeodomains (Laughon, 1991). This raises
the possibility that only a limited set of amino acids can occupy these positions and make
specific base contacts in the context of homeodomain structure and DNA docking.
The POU-homeodomain of the Oct-1 transcription factor participates in
prototypical homeodomain-DNA interactions in that specific recognition in the major
groove is mediated by residues asparagine (N) 51 and valine (V) 47 (Klemm et al., 1994).
Oct- 1 is a founding member of the POU domain subfamily of homeodomain transcription
factors (Herr et al., 1988) which recognizes the 5' half of the consensus octamer site (5'-
ATGCAAAT-3') with the POU-specific domain and the 3' half (5'-ATGCAAAT-3') with
the POU-homeodomain (Figure 1). In the DNA-protein complex, the adenine at position
7 (5'-ATGCAAAT-3') is contacted by POU-homeodomain residue N51. This interaction
corresponds to that observed in the engrailed:DNA (Kissinger et al., 1990) and
MATa2:DNA (Wolberger et al., 1991) complexes, in which the asparagine accepts a
hydrogen bond from the N6 of adenine and donates a hydrogen bond to the N7.
Asparagine 51 is one of the most highly conserved residues in all homeodomains, and its
interaction with the core adenine is believed to be a signature feature of homeodomain-
DNA binding. The thymine at position 8 (5'-ATGCAAAT-3') interacts with V47 via a
van der Waals contact involving the thymine methyl group (Klemm et al., 1994).
Homeodomain residue 47 is most often either an isoleucine or a valine, and in the
engrailed:DNA cocrystal structure, isoleucine 47 contacts the counterpart thymine (5'-
TAAT-3') via an analagous interaction. Thus, Oct-l POU-homeodomain residues V47
and N51 represent determinants which are used by most homeodomains for base-specific
contacts to the TAAT core sequence in the major groove of DNA.
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Figure 1. The Oct-i POU domain bound to DNA. Residues 47 and 51 in helix 3 of the
POU-homeodomain are shown in ball-and-stick representation interacting with adenine 7
(5'-ATGCAAAT-3') and thymine 8 (5'-ATGCAAAI-3') of the octamer sequence,
respectively. This figure was generated by MOLSCRIPT (Kraulis, 1991) using the
coordinates of Klemm et al. (1994).
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In order to examine how the structural context of homeodomain-DNA binding
constrains the nature of amino acids involved in specific interactions with the TAAT core
sequence, an Oct-1 POU domain bacterial expression library was generated in which
residues 47 and 51 in the POU-homeodomain were randomized. This library was
prepared so that the DNA-binding of a large number of POU domain variants could be
screened by the direct binding of radioactive DNA probes on nitrocellulose filters. This
library has been used to investigate what residues at position 47 and 51 are consistent
with binding to the octamer consensus site. In addition, the library has been used to
detect Oct-1 POU domain variants which have novel DNA-binding specificities, and
which can alter the binding specificity of a transcriptional regulatory complex which
depends upon Oct-i for DNA recognition.
MATERIALS AND METHODS
Construction and screening of the bacterial PA-Oct-l POU domain expression library. A
Protein A-Oct-1 POU-domain expression library was constructed by a strategy we refer
to as Deletion Insertion Randomization (DIR). DIR is useful when restriction sites
flanking a region desired to be randomized are not available and cannot be engineered
silently. Oligonucleotide-mediated mutagenesis (Sayers et al., 1992) is employed using a
population of oligonucleotides which has been synthesized to randomize codons. In
order to avoid selective hybridization of the oligonucleotides that contain bases which are
complementary to the wild-type ssDNA substrate, a previous round of mutagenesis is
performed that deletes the region of desired randomization. The construct containing the
deletion is used to prepare a ssDNA substrate for the insertion randomization
mutagenesis. A fragment encoding a portion of the Oct-1 POU domain (amino acids
345-441(Sturm et al., 1988)) was cloned into the vector pBS+(Stratagene). ssDNA was
prepared using VCSM13 helper phage (Stratagene) and XLl-Blue host strain according
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to the manufacturer's protocol. This ssDNA was the substrate for mutagenesis
performed using the oligonucleotide-directed mutagenesis system version 2 (Amersham)
according to the manufacturer's instructions. Deletion mutagenesis, designed to delete
the region of DNA encoding POU-homeodomain residues 45-53 (homeodomain
numbering scheme of Qian et al., 1989) in helix 3, was accomplished using the
oligonucleotide 5'-CAATATGGAAAAAGAGGTGCAGAAAGAAAAAAGAATCC-3'.
From the resulting construct, 45-53, ssDNA was generated and used as a template for
insertional mutagenesis designed to replace the deleted region with the codons for
homeodomain residues 47 and 51 randomized as NNG/C. The mutagenic
oligonucleotide used for this insertion was 5'-ATATGGAAAAAGAGGTGATTCGT
NNG/C TGGTTCTGTNNG/C CGCCGCCAGAAAGAAAAAAGAATCAACC-3'. The
products of the insertional mutagenesis reaction were used for transformation of XL1-
Blue strain. 9500 transformed colonies were scraped from LB-agarose ampicillin
(100ug/ml) plates, pooled, and plasmids were prepared by standard protocols. The
fragment encoding the POU domain was excised from the plasmid pool and ligated into
vector pRIT2T (Pharmacia) so as to generate an in frame fusion of the full POU domain
(residues 270-411 (Sturm et al., 1988)) with the Protein A gene product of S. aureas. The
ligation products were used to transform E. coli strain N4830 which was plated on LB-
agar ampicillin plates for library screening. A random distribution of nucleotides at
homeodomain codons 47 and 51 was confirmed by dideoxysequencing of a number of
individual expression plasmids and by sequencing a sample of the total pooled expression
library.
After plating, colonies were allowed to grow for 24 hr at 300 C before transfer to
nitrocellulose filters (132mm, BA85/23 Schleicher and Schuell). After marking the
position of filters on plates, the filters were lifted and incubated colony side up on a new
set of plates at 420C for 2 hr to induce fusion protein expression. Colony lysis was
achieved by exposure to chloroform vapor for 10 min and then immersion in lysis buffer
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(100 mM Tris-HC1 (pH 7.8), 150 mM NaCl, 5 mM MgC12, 1.5% bovine serum albumin
Fraction V (heat shock), 400 ig/ml lysozyme) (25mVl/filter) for 10 min at 250C. After air
drying, filters were then processed through a denaturation/renaturation cycle. Filters
were gently shaken in buffer J (25 mM Hepes (pH 7.9), 25 mM NaCl, 5 mM MgC12, 0.5
mM DTT) plus 6M Guanidine HC1 for 5 min at 40 C. The Guanidine HC1 concentration
was diluted two fold in each of 5 steps with the removal of half of the buffer and the
addition of an equal volume of buffer J, after which filters were washed twice with
buffer J. Each step was incubated for 5 min at 4°C. Filters were then incubated in
blocking buffer (50 mM Tris-HCl (pH 7.9), 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 5%
BSA Fraction V) (50 ml/filter) with gentle shaking for 1 hr at 250 C, then rinsed twice, 5
min each, with binding buffer (20 mM Hepes (pH 7.9), 50 mM KCI, 1 mM EDTA, 0.7
mM DTT, 0.025% NP40). During the lysis, denaturation/renaturation, and blocking
steps, each filter was placed in a separate petri dish for the incubation. Filters were then
gently shaken in binding buffer plus 5 jig/ml denatured sonicated salmon sperm DNA and
32 P-labelled probe at a final 1-2 x 106 cpm/ml (10-1 0 M) for 1 hr at 25°C. Filters were
then washed twice for a total of 15 min with binding buffer (500 ml for up to 4 filters),
blotted dry, and then exposed to Kodak X-OMAT AR film at -700 C with an intensifying
screen for 12-24 hr. Positive colonies were picked, patched onto new plates and
rescreened. Plasmids were isolated from colonies which rescreened positive and
sequenced by dideoxysequencing to determine the residues encoded at positions 47 and
51 of the homeodomain. Probes used for screening were derived from cloning the
fragment
5'-GATCCTATGCAANNGACC-3'
3'-GGATACGTTNNCTGGAGCT-5'
into the XhoI and BamHI sites of pBSKII+ (Stratagene). All 16 variants were obtained,
verified by dideoxysequencing and excised for use as probes by digesting with XbaI and
Asp718. Fragments were labelled by the large (Klenow) fragment of E. coli DNA Pol I
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in the presence of dGTP, dCTP, dTTP, and a-3 2 P-dATP, and then gel-purified on
nondenaturing polyacrylamide gels.
5000 colonies were screened with the probe containing the octamer consensus
sequence. For screening with the pools of mutant probes, 4000 colonies were screened
by each probe pool, with each of the four probes in the pool at an equal concentration of
1-2 x 106 cpm/ml (-10 - 10 M).
Expression of fusion proteins. Selected variants were expressed in E. coli N4830 strain
and were purified by affinity chromatography on IgG-Sepharose as described previously
(Kristie & Sharp, 1990). The concentration of each PA fusion protein was determined by
densitometric analysis of Coomassie-stained SDS-PAGE-resolved proteins using bovine
serum albumin (Boehringer Mannheim) as standard.
Electrophoretic Mobility Shift Assays. Relative affinities of variants were determined by
electrophoretic mobility shift assays using the same probes as those used for colony
screening. DNA-protein-binding reactions contained 3-30 pg of DNA probe, 10 ng of
poly[d(I-C)]/poly[d(I-C)], 10 mM Hepes (pH 7.9), 0.5 mM EDTA, 50 mM KC1, 0.75
mM DTT, 4% Ficoll-400, 300 gg/ml of bovine serum albumin, and 1-8000 pg of PA-Oct-
1 POU domain variant in a total volume of 10 gl. The concentration of DNA probe was
always at least one order of magnitude below the apparent dissociation constant.
Reactions were incubated at 300 C for 30 minutes and resolved in 4% nondenaturing
polyacrylamide gels (Pomerantz et al., 1992). The protein-DNA and free DNA
complexes were quantitated using a Molecular Dynamics Phosphorimager with
ImageQuant 3.15 and 3.22 software. Apparent dissociation constants were determined
as the inverse of the slope of the line derived from plotting fraction of probe
bound/fraction of probe unbound vs. total PA-POU domain protein concentration. In all
cases the lines consisted of at least four points. C1 complex formation assays were
performed using the HSVaO probe (HSV a/IE element: 5'-GTGCATGCTAATGATATT
CTTGGGG-3') (Kristie et al., 1989) or a mutated version (HSV al/IE "GG" element: 5'-
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GTGCATGCTAGGGATATTCTTTGGGG-3') that was generated by the oligonucleotide
directed mutagenesis system version 2 (Amersham) according to the manufacturer's
instructions. DNA-protein-binding reactions were performed as described above using
0.4-0.8 ng of DNA probe, 300 ng of poly[d(I-C)]/poly[d(I-C)], and, where indicated, 15
ng of PA- aTIF and 1 l of a chromatographic fraction containing the HeLa cell C1 factor
(Pomerantz et al., 1992).
Random Binding Site Selection. The probe used for random binding site selection was
generated by annealing the following two oligonucleotides and polymerizing with
Klenow in the presence of dGTP, dCTP, dTTP, and a-3 2P-dATP Primer R: 5'-GGCTG
AGTCTGAACGGATCCN 13 CCTCGAGACTGAGCGTCG-3'; Primer A: 5'-CGACGCT
CAGTCTCGAGG-3'. For the first round of selection 50 pg of PA-POU domain variant
was incubated with 5 ng of probe in DNA-protein-binding reactions under the conditions
described above in the absence of any poly[d(I-C)]/poly[d(I-C)]. In each round, reactions
were electrophoresed as described above, gels were dried, exposed to film, and the DNA
protein-complexes were excised from the dried gel for elution and PCR amplification of
bound fragments (Blackwell & Weintraub, 1990) using Primer A above and Primer B: 5'-
GGCTGAGTCTGAACGGATCC-3'. A contamination control was processed in parallel
starting from a gel slice containing no protein-DNA complex. In all cases this control did
not produce any detectable PCR products. Approximately 1 ng of amplified product was
used in the binding reaction of the next round of selection. For the second and third
rounds, 50 pg of PA-POU domain variant was used; 10 pg was used in the fourth round.
The amplified products of the fourth round of selection were digested with BamHI and
XhoI and ligated into the vector pBSKII+. Plasmids were derived from transformants
and sequenced by dideoxysequencing.
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RESULTS
A bacterial expression library was generated in which POU-homeodomain
residues 47 and 51 were simultaneously randomized. In this library, the Oct-1 POU
domain was fused to protein A (PA) of S. aureus to facilitate the expression, purification
and analysis of individual variants. The library was screened for the binding of
radioactive DNA probes using conditions similar to those originally described for the
screening of cDNA expression libraries by Singh et al. (1988) and Vinson et al. (1988)
(see Materials and Methods). A similar procedure has been described by Lorimer et al.
(1992).
The nature of residues at positions 47 and 51 which can participate in the specific
recognition of an octamer site was determined by probing the library with a DNA
fragment containing the octamer consensus sequence (5'-ATGCAAATGA-3'). As shown
in Table 1, the combination of residues that was most efficiently detected in the screen
was the combination found in the wild-type protein, valine at position 47 and asparagine
at position 51. All of the variants detected can be segregated into classes according to the
residue at position 51. Surprisingly, in addition to a class containing asparagine at
position 51, a class containing arginine at this position was also detected, as well as a
single variant containing glutamine at position 51 and valine at position 47.
The relative effects of amino acid substitutions on binding affinity were
determined by comparison of a representative panel of variants to the wild-type protein
(Table 1). Of those analyzed, the wild-type protein exhibited the highest affinity for the
fragment. Variants containing only substitutions of V47 had minor reductions in affinity,
the largest a 6.5-fold reduction for the G47 N51 variant. The greatest reduction in
binding affinity was observed for the V47 Q51 variant, which had a 1100-fold reduction
in affinity. Two representatives of the R51 class of variants, G47 R51 and R47 R5 1, had
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intermediate affinities with reductions of 23- and 32-fold, respectively, compared to the
wild-type protein.
TABLE 1 - RESULTS OF SCREENING WITH
5'-ATGCAAATGA-3'
47 51 #isolatesa #predicted b isol./pred. affinityC
Vd Nd 8 10 0.80 1
R N 5 15 0.33 3.0
T N 2 10 0.20 nd
N N 1 5 0.20 2.8
I N 1 5 0.20 nd
C N 2 5 0.40 nd
G N 1 10 0.10 6.5
H N 1 5 0.20 4.7
R R 13 44 0.30 32
G R 7 30 0.23 23
S R 2 44 0.05 nd
N R 1 15 0.07 nd
A R 2 30 0.07 nd
C R 1 15 0.07 nd
H R 1 15 0.07 nd
T R 2 20 0.10 nd
V Q 2 10 0.20 1100
a- 50 0 0 colonies screened
bthe expected frequency of that variant in 5000 colonies of the library. codons
47 and 51 were randomized as NNG/C; 32 possible codons at each position,
total complexity of library is 1024
Crelative dissociation constant, normalized to that of the wild-type protein
dresidue found in wild-type protein
The large variability of residues at position 47 detected in the screen suggested
only a moderate contribution of V47 to the binding affinity and specificity of the POU-
domain. The minimal effects on affinity observed for its substitution with chemically
diverse side chains were consistent with this notion. On the other hand, the greater
apparent selectivity at position 51 suggested a more critical role for N51, which was
supported by the 1100-fold reduction in binding affinity upon substitution with the
chemically similar glutamine. The intermediate affinity of variants containing arginine at
51 suggested that their specificity might be quite different from that of the wild-type
protein. Therefore, the specificity of variants with substitutions at 51 for the adenine
90
residue (adenine 7, Fig. 1) contacted by N51 of the wild-type protein (5'-
ATGCAAATGA-3') was examined.
The V47 Q51, R47 R51, and G47 R51 variants were compared to the wild-type
protein (V47 N51) for binding to fragments containing nucleotide substitutions of
adenine 7 (Table 2). All variants exhibited a preference for adenine at nucleotide 7;
however, the wild-type protein had a much higher specificity for this residue.
Specifically, the substitution of adenine with guanine, thymine, and cytosine resulted in
reductions in affinity of 300-, 1100-, and 45000-fold, respectively, for the wild-type
protein. In comparison, for the V47 Q51 variant, these substitutions reduced affinity by
49-, 75-, and 87-fold, respectively, while for the R47 R51 variant, reductions of 1.4-, 20-,
and 19-fold, respectively, were observed. Thus, asparagine at position 51 is not only
required for the highest affinity interaction with the octamer site, it also determines the
greatest selectivity for adenine at nucleotide position 7.
TABLE 2 - SPECIFICITY OF VARIANTS FOR NUCLEOTIDE 7
V47N51a V47Q51a R47R51a G47R51 a
5'-ATGCAAATGA-3' 1 1100 32 23
5'-ATGCAAGTGA-3' 300 54000 44 69
5'-ATGCAACTGA-3' 45000 96000 610 500
5'-ATGCAATTGA-3' 1100 83000 650 700
arelative dissociation constant, normalized to that of the wild-type protein for the octamer
consensus sequence
The randomized expression library was also used to explore what other
combinations of homeodomain residues at 47 and 51 and nucleotides at positions 7 and 8
could provide high affinity homeodomain-DNA interactions. The library was probed
with fragments of DNA containing nucleotide substitutions at these positions. Since
much of the specificity of binding was determined by interactions mediated by nucleotide
7, pools of probes were grouped according to the identity of this residue. For example,
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the "CN" pool consisted of probes 5'-ATGCAACAGA-3', 5'-ATGCAACTGA-3', 5'-
ATGCAACCGA-3', and 5'-ATGCAAGGA-3'. Interestingly, when the library was
probed with either the "CN" pool or the "TN" pool, no positive colonies were observed.
This suggested that neither cytosine nor thymine at position 7 could mediate an
interaction that could contribute enough affinity for detection by this screen. When the
library was probed with the "GN" pool, a single variant, R47 R51, was detectable at a low
frequency (4 positives, 35 predicted (4000 screened)). This variant was characterized
further.
It was possible that the arginine substitutions at positions 47 and 51 in the R47
R51 variant mediated novel interactions with nucleotides other than those at positions 7
and 8. This variant had much less selectivity for nucleotide 7 than the wild-type protein
(Table 2) and yet was detected in both the "GN" pool screen and in the initial screen with
the unsubstituted octamer consensus sequence. To directly compare its nucleotide
preferences at all positions in the binding site with that of the wild-type protein, a random
binding site selection assay was employed (Blackwell & Weintraub, 1990; Pollock &
Triesman, 1990). The wild-type protein (V47 N51) and the R47 R51 variant were
challenged in four rounds of binding site selection, along with the R47 N51 variant as a
control for the effects of the substitution of V47 with arginine. At least twenty five
sequences were determined for each protein from the pool of sites that were selected in
the fourth round (Figure 2A, C, E). Consensograms (Wilson, D. et al., 1993) were
derived from these sequences (Figure 2B, D, F). As shown previously (Verrijzer et al.,
1992), the wild-type POU domain selected a consensus octamer site (5'-TATGCAAAT-
3') with strict preferences for nucleotides at positions -1 through 8 (Fig. 2A, B). In
contrast, the R47 R51 variant selected sites with reduced stringency, especially at
positions 7 and 8 (Fig. 2C, D). Although this variant prefers adenine at position 7, this
preference is not as strong as it is for the wild-type protein: guanosine was selected at that
position 6/26 times for R47 R51 and 0/25 for V47 N51. Thus, substitution of N51 with
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Figure 2. Binding site sequences selected by the wild-type Oct-l POU domain (V47
N51) and the R47 R51 and R47 N51 variants. (A, C, E) Sequences of sites isolated after
four rounds of selection. (B, D, F) Consensograms (Wilson, D. et al., 1993) derived from
the selected sequences.
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oo aATATCAATA G
CC TCTAGCAATG CC
ao aGTATTAAATT Go
CC TTGCAAATTAG CC
CC GTmAGCAATTAa G
a GaTTATaGCAAT G
aa ATATGCAATCAC Go
CC AGCTGLCAATGC CC
CC TTATaAATTC CC
aa GTATGCAATATC Go
aa OTATAATT aG
Go GCATWACAAATA Go
o CGTATLcAATT Go
Gaa GTATGCAATT ] aG
Ca TmrC AA"M aGo G hAI'Ga T G
CC CTTGTAAATTAC CC
G GoaATaCAATGA Go
G GCTA~TGKAATT Ga
CC TTGTAATAGCC CC
CC ATATGCiAA C CC
G GATGCATG Go
Ga aGATATGQCAATA G
G GTATGa c TAC a
CC OTATCAAATTAC CC
CC ATATGCAAATCCC CC
CC ATATCAAATAAC CC
CC CATACAA.GTAC CC
CC ATATGCAAATCCC CC
CC GTATTCAAAACA CC
GG CTCATGCAAAACA Ga
CC AGATGCAAAGTAG CC
CC ATTATGCAAGACA CC
CC AATATGTAAAGCA CC
Ga GTTATGTAAATCA Go
G GGTATGCAAAACA Go
Ga GrTATGTAAATTC (a
CC GTATGCA~TGCG CC
CC TATGCAAAGTCAC CC
CC TTTAT(OCAAATCG CC
GG GaTTATaCAAAAC Go
CC GTATGCAACaTAG CC
CC ATATGCAAATCCC CC
CC TTATGCAAAATCC CC
CC GTATGChAAACAC CC
CC ATATGCAAGGTAC CC
CC TTATGCAAG~CAC CC
CC TTATGCAAAACAC CC
CC TCQ.ATT.TAGa.C CC
CC ATGCTACTGGGC CC
CC TTTGTGICAAGTAC CC
CC TTGCAAATCGCC C
CC TTITGrCAATCCC CC
aGo TGaTaTGCAAATGA 
Go GGATATCOCAAATC Ga
Go GTCCTATGCAA Go
CC TThTGCAAAGCOC CC
CC GAThTGKCA2AACC CC
CC AATATaCAATCC CC
CC TTTGATAATCCC CC
CC ATATGUTALTCCC CC
G0 aGCGATATGCTAA Ga
aG GCGCTTATGCAAA ac
G00 GTTGCAAATCC Ga
Go G'AATATGLCAATC GG
CC ATATGTAAATGCC CC
G GaaTacTAATGA GG
CC TATGTAACGOAC CC
CC ATGOAAATCCGCGOC
CC AIhTGAAATCCC CC
CC GTATGCAAATTAC CC
CC GTATGCRAATGAC CC
CC TTATTGTAATC CC
a CCGKATGCAAATC GG
CC GTTGTAAGCAC CC
Go GTTGCAAACCT Go
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arginine results in a change in the "adenine requirement" at position 7 to a "purine
requirement." The R47 R51 variant also exhibits much less stringency of selection at
position 8 as compared to the wild-type. Adenine and thymine were selected equally by
the variant with less preference for guanosine and cytosine while only thymine was
selected by the wild-type protein. The effect at position 8 is partially attributable to the
substitution of V47 with arginine (Fig. 2E, F). It appears from the sequences selected,
that the R47 R51 variant did not select any nucleotide at any position with greater
stringency than did the wild-type protein. This suggests that arginine, either at position
47 or 51, does not make unique nucleotide-specific contacts at any position in the
selected site.
The relaxed specificity of the R47 R51 variant suggested its potential to redirect
the formation of Oct-l-dependent transcriptional regulatory complexes to novel
sequences that are not efficiently recognized by the wild-type protein. We sought to test
this possibility using as a model system the formation of the multiprotein C1 complex on
the Herpes Simplex Virus (HSV) a or immediate-early (a/IE) enhancer element.
Formation of the C1 complex is dependent on the binding of the element by the Oct-1
POU domain and the viral aTIF protein (VP16, Vmw65, ICP25)(McKnight et al., 1987;
Gerster & Roeder, 1988; O'Hare & Goding, 1988; Preston et al., 1988; Kristie et al.,
1989; Stern et al., 1989), on the specific recognition of the Oct-1 POU-homeodomain
surface by aTIF (Pomerantz et al., 1992; Lai et al., 1992), and on the presence of the
cellular C1 factor (HCF) (Kristie & Sharp, 1993; Wilson, A.C. et al., 1993). Some
nucleotide substitutions in the octamer-related sequence in this element should impair
binding of the wild-type Oct-1 protein while having only a minimal effect on the binding
of the R47 R51 variant. Formation of the regulatory complex on this novel element
would then be dependent on the R47 R51 variant, and not possible with the wild-type
protein. The combination of nucleotide substitutions at positions 7 and 8 which would
provide the greatest discrimination in binding between the wild-type protein and the R47
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R51 variant was determined. The R47 R51 variant was directly compared to the wild-
type protein for binding to 16 probes containing all combinations of nucleotides at
positions 7 and 8. As shown in Table 3, the sequence with the greatest preference (260
fold) for the variant contained guanosine at both positions 7 and 8 (5'-ATGCAAGGGA-
3').
The double guanosine substitution was incorporated into the HSV a/IE element
(5' -ATGCTAGGGATATTCTTTGG-3' (HSV a/IE "GG")) and tested for the formation
of the C1 complex in the presence of aTIF, the C1 factor, and either the wild-type or
variant Oct-1 POU domain. The R47 R51 POU domain variant was first compared to
the wild-type protein for formation of the C1 complex on the unsubstituted HSV /IE
element (Figure 3). The R47 R51 variant was clearly capable of forming the complex (cf.
lanes 2 and 4), although 14 fold more protein was required to attain similar levels of
DNA binding. When normalized on the basis of DNA binding activity, the variant was
found to have only a 2.4-fold lower ability to form the complex than the wild-type protein
TABLE 3 - RELATIVE SPECIFICITY OF V47 N51 AND R47 R51
V47N51a R47R51a VN/RRb
5'-ATGCAAATGA-3' 1 32 0.031
GT 300 44 6.8
CT 45000 610 74
TT 1100 650 1.7
AC 5.3 120 0.04
AA 7.1 79 0.09
AG 16 130 0.12
GC 37000 1000 37
GA 3900 100 39
GG 39000 150 260
CC 29000 130 220
CA 39000 810 48
CG 75000 710 110
TC 1700 1100 1.5
TA 5300 980 5.4
TG 4200 1200 3.5
arelative dissociation constant, normalized to that of the wild-type protein binding
to the octamer consensus
bthe dissociation constant for the V47 N51 protein divided by that for the R47 R51
variant
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Figure 3. The R47 R51 variant changes the DNA-binding specificity of an Oct-l-
dependent regulatory complex. Wild-type (V47 N51, 25pg in lanes 1, 2, 5 and 6, 350 pg
in lanes 9 and 10) and variant (R47 R51, 350 pg) PA-Oct-1 POU domain fusion proteins
were incubated in DNA-protein-binding reactions in the absence (-) or presence (+) of 15
ng of PA- aTIF and 1 .1 of a chromatographic fraction containing the HeLa cell C1 factor
as indicated. Reactions included either the unsubstituted HSV a/IE element (5'-
ATGCTAATGATATTCTTTGG-3') (lanes 1-4) or the double guanosine substituted HSV
a/IE "GG" element (5'-ATGCTAGGGATATTCMIT GG-3') (lanes 5-10) as probe. The
positions of the multiprotein C1 and POU domain:DNA complexes are indicated with
arrows.
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on the unsubstituted element. When the HSV a/IE "GG" element was used, no binding of
the wild-type POU domain was detectable even at concentrations 14 fold higher than that
required to bind the unsubstituted element (lanes 5 and 9), and upon addition of aTIF and
the C1 factor, no complex formation was evident (lanes 6 and 10). In contrast, the R47
R51 variant bound the HSV a/IE "GG" element to an extent similar to that for the
unsubstituted element (lane 7) and was capable of efficiently forming the C1 complex
with aTIF and the C1 factor (lane 8). Therefore, the R47 R51 variant can be used to alter
the DNA-binding specificity of a transcriptional regulatory complex which depends upon
Oct-i for DNA recognition.
DISCUSSION
Transcription factors utilize structural modules to recognize specific DNA
sequences (Pabo & Sauer, 1992). Some modules, such as the zinc finger originally
discovered in TFIIIA (Miller et al., 1985), accommodate different sets of amino acid
determinants so that DNA binding specificity can vary within the framework of a
conserved domain structure (Pavletich & Pabo, 1991, 1993; Fairall et al., 1993). Other
modules appear to be specialized for the recognition of particular sequences, such as
those of the basic-helix-loop-helix (CANNTG) (Murre & Baltimore, 1992) and nuclear
hormone receptor (AGNNCA (half site)) (Evans, 1988) families. The homeodomain has
apparently evolved with a constrained specificity for a binding site with a TAAT core.
The Oct-1 POU-homeodomain has been used to test the stringency of determinants that
mediate recognition of the TAAT core in the major groove.
Among all possible interactions determined by Oct-i POU-homeodomain
residues 47 and 51 and the nucleotides at position 7 and 8 in the octamer binding
sequence (5'-ATGCAAAT-3'), the N51-adenine 7 and V47-thymine 8 interactions
provide the highest affinity and greatest degree of specificity. The structure of the
homeodomain and its mode of docking against DNA probably impose greater constraints
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on the amino acid 51-nucleotide 7 interaction than on the amino acid 47-nucleotide 8
interaction. Fewer residues were detected in the screens at position 51 than at 47, and
substitution of either N51 or adenine 7 had a larger effect on affinity and specificity than
did substitution of V47 or thymine 8. The fact that all variants analyzed had higher
affinities for sites containing adenine at position 7 than those containing other bases at
that position suggests that adenine at the third position of the homeodomain subsite
(AAAT) is most compatible with the spatial architecture of the homeodomain even when
residue 51 is not the highly conserved asparagine. In accord with these results, Botfield
et al. (1994) have found that in the homologous Oct-2 POU-homeodomain, N51 provides
the highest affinity interaction with the wild-type octamer sequence when compared to 19
substituted variants.
The ability to achieve reasonable affinity (-10- 9 M) for DNA with arginine at
position 51 was surprising, given its lack of chemical similarity to asparagine. In
addition, arginine is not found in this position in any natural homeodomain. Arginine at
51 is probably not making a nucleotide-specific contact and it is possible that this residue
contributes to binding affinity by ionic interaction with the sugar-phosphate backbone.
Alternatively, the purine requirement at position 7 that is observed for the R47 R51
variant may reflect an interaction of arginine with the N7 of the base. A similar
specificity, determined by an arginine positioned in the major groove by an a helix, has
been invoked based upon the Hin recombinase:DNA recombination half site crystal
structure (Feng et al., 1994). The relaxed sequence specificity of the R47 R51 variant
allows it to nucleate the formation of a transcriptional regulatory complex on a DNA
sequence element which is not efficiently bound by wild-type Oct-1. Since formation of
the C1 complex is critically dependent on the presentation of residues on the surface of
helices 1 and 2 (Pomerantz et al., 1992; Lai et al., 1992) we conclude that substitution of
residues 47 and 51 with arginine does not drastically perturb homeodomain structure.
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Since the R47 R51 variant binds with reasonable affinity and can participate in the
formation of regulatory complexes, it is reasonable to question the absence of this variant
set of amino acids in the known sequences of homeodomains. Both the reduced affinity
and specificity of the variant, relative to the wild-type protein, may preclude its utility in
vivo. The R47 R51 variant binds the octamer sequence with thirty-fold lower affinity
than the wild-type protein. In addition, its reduced specificity allows it to recognize
many more sequence variants at a given protein concentration than the greater specificity
of the wild-type protein would allow. The partitioning of the variant between its
"specific" and "nonspecific" sites may make the occupancy of an individual target
sequence without inappropriate action at other sites impossible at physiological levels of
expression of the protein.
Other studies have altered the binding specificity of homeodomains by
substitution of residue 50 since this residue is an important determinant of specificity for
nucleotides 3' to the TAAT core (Hanes & Brent, 1989, 1991; Treisman et al., 1989;
Percival-Smith et al., 1990). However, for POU domain proteins the residue at this
position (cysteine) does not confer sequence selectivity and can be substituted without
effect (Ingraham et al., 1990; Verrijzer et al., 1992). Consistent with this is that the POU
domain does not select nucleotides 3' to the octamer site with a high degree of preference.
The 3' boundary of sequence recognition by POU-homeodomains appears to be much
more critically dependent on residues 47 and 51. It is presently unclear why cysteine 50
is absolutely conserved among POU domain proteins.
The interactions mediated by residues 47 and 51 do not appear to be independent.
For example, the effect of the substitution of N51 with arginine is dependent on what
residue is at position 47. This substitution reduces the affinity for the octamer consensus
sequence by 11-fold when residue 47 is arginine but only by 3.5 fold when residue 47 is
glycine (Table 1). In addition, the residue at position 51 also influences which nucleotide
is selected at position 8 when residue 47 is arginine. The R47 N51 variant has less
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selectivity for thymine at position 8 than does the wild-type protein, and this selectivity is
further reduced for the R47 R51 variant (Figure 2). We also note the lack of detection of
a variant containing valine at position 47 and arginine at position 51. The frequency of
this variant in the library is predicted (29/5000) to be larger than most of the variants that
were detected in the screen performed with the unsubstituted octamer sequence as probe.
This implies that this variant should have been detected if its affinity (off-rate) for the
octamer sequence fell within the large range of affinities exhibited by those variants that
were detected. The combination of valine at position 47 and arginine at position 51 may
somehow be incompatible with homeodomain structure or DNA-binding.
The interaction between residues 47 and 51 is probably related to the steric
constraints that are imposed upon them as they pack into the major groove. The
advantage of having wild-type residues V47 and N51 is not only due to their individual
potentials for base-specific contacts but also to their ability to be sterically accommodated
in the protein-DNA complex. It is striking that the V47 Q51 variant, which has the
identical functional groups for nucleotide recognition and which differs from the wild-
type only by a methylene group, has a 1100-fold reduced affinity for the octamer
consensus. The substitution of either residue 47 or 51 with the much larger arginine may
introduce steric interactions that reduce the density of packing of the side chains of helix
3 into the major groove, and therefore alter the complementarity of the protein surface to
the DNA. This is evident in the consensograms of Figure 2. The wild-type
consensogram presents a profile of selected nucleotides with nearly absolute preferences
and clear boundaries on either side of the binding site. In contrast, the consensograms of
the R47 N51 and R47 R51 variants exhibit a breakdown of binding-site stringency. The
arginine substitutions affect the selection of nucleotides at positions other than 7 and 8,
which may reflect the inability to pack the arginine side chain in a way which does not
perturb other interactions. For example, even the nucleotide selected at position 4, which
is within the POU-specific domain subsite, is influenced by the substitution of 47 and 51.
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This implies that the packing of residues in helix 3 also impinges upon the binding
specificity of the POU-specific domain, and reveals an interdependence of the POU-
specific and POU-homeo subdomains that must arise from the spacing of subsites that is
strictly preferred by the POU domain. Although their are no protein-protein interactions
observed between the subdomains in the Oct-1 POU domain:DNA complex, and the
linker between them is disordered, changing the spacing of subsites reduces the affinity of
the POU domain 10-100 fold (Klemm et al., 1994).
The surprising detection of R51 variants attests to the utility of the
randomization/screening approach. This technique relies upon the detection of direct
binding to radiolabelled DNA probes and allows for the screening of a large number of
proteins without competition between variants for binding to the probe. Such an
approach should complement others (Youderian et al., 1983; Rebar & Pabo, 1994) for the
isolation of transcription factors with new DNA-binding specificities that will provide
useful tools and advance the understanding of protein-DNA interactions.
We conclude that it is probably not possible to alter homeodomain DNA-binding
specificity by the substitution of residues 47 and 51 without sacrificing affinity and the
ability to discriminate between sites. The homeodomain emerges as a module which is
limited in its ability to recognize different DNA sequences and which has evolved the
capacity to participate in other mechanisms of regulatory specificity such as protein-
protein interactions. The constraints on homeodomain residues 47 and 51 emphasize that
in protein-DNA recognition, the potential interactions that a particular amino acid
residue may specify are critically dependent on the structural context determined by the
folding and DNA-docking of the module in which it is found. Therefore, the spatial
architecture of a DNA-binding domain may greatly constrain which amino acid residues
can serve as its determinants of DNA recognition.
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CHAPTER IV
STRUCTURE-BASED DESIGN OF TRANSCRIPTION FACTORS
This chapter originally appeared in Science 267: 93-96 (1995).
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ABSTRACT
Computer modeling suggested that transcription factors with novel sequence specificities
could be designed by combining known DNA-binding domains. This structure-based
strategy was tested by constructing a fusion protein, ZFHD1, that contained zinc fingers 1
and 2 from Zif268, a short polypeptide linker, and the homeodomain from Oct-1. The
fusion protein bound optimally to a sequence containing adjacent homeodomain
(TAATTA) and zinc-finger (NGGGNG) subsites. When fused to an activation domain,
ZFHD1 regulated promoter activity in vivo in a sequence-specific manner. Analysis of
known protein-DNA complexes suggests that many other DNA-binding proteins could be
designed in a similar fashion.
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Transcription factors are critical regulators of gene expression. The rational
design of transcription factors with novel DNA-binding specificities and regulatory
activities will provide powerful reagents for biological research and gene therapy. The
recent determination of a series of structures of protein-DNA complexes has facilitated a
design strategy that uses computer modeling to predict how DNA-binding domains could
be combined to generate novel specificities. We have explored this strategy by designing
and testing a zinc finger-homeodomain fusion protein.
Computer modeling studies were used to visualize how zinc fingers might be
fused to the Oct-i homeodomain. The known crystal structures of the Zif268-DNA (1)
and Oct-l-DNA (2) complexes were aligned by superimposing the double helices in
several different registers. Two arrangements were particularly interesting. In one
alignment the COOH-terminal end of zinc finger 2 was 8.8 A away from the NH2-
terminal arm of the homeodomain (Fig. 1), suggesting that a short polypeptide linker
could connect these domains. In this model the fusion protein would bind a hybrid DNA
site with the sequence 5'-AAATNNTGGGCG-3'. The Oct-1 homeodomain would
recognize the AAAT subsite, zinc finger 2 would recognize the TGG subsite, and zinc
finger 1 would recognize the GCG subsite. There was no possibility for steric
interference between the zinc fingers and the homeodomain in this arrangement.
Superimposing the DNA duplexes in other registers generated a second plausible
arrangement for a hybrid protein (3); however, this model was not as favorable since
there was a risk of steric interference between the zinc fingers and the homeodomain.
The design strategy was tested by construction of a fusion protein, ZFHD1, that
contained fingers 1 and 2 of Zif268, a glycine-glycine-arginine-arginine linker, and the
Oct-1 homeodomain (Fig. 2A). A glutathione S-transferase domain was added to
facilitate expression and purification, and the DNA-binding activity of this fusion protein
was determined by selecting binding sites from a random pool of oligonucleotides. After
four rounds of selection, 16 sites were cloned and sequenced (Fig. 2B). Comparing these
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Figure 1. Model of a zinc finger - homeodomain hybrid. Finger 1 of Zif268 is depicted
in purple, finger 2 in yellow, and the Oct-i homeodomain in red. The DNA is blue with
the base pairs in the AAAT and TGGGCG subsites highlighted in cyan; the hybrid
protein recognizes a sequence of the form 5'-AAATNNTGGGCG-3'. The Ca of Gly 59
(COOH-terminus of finger 2) is 8.8A from the Ca of Arg 2 (the first homeodomain
residue visible in the crystal structure) (13). This figure was generated with Insight II
(Biosym Technologies, San Diego).
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Figure 2. Selection by ZFHD1 of a hybrid binding site from a pool of random
oligonucleotides. (A) Structure of the fusion protein used to select binding sites (14). The
underlined residues are from the Zif268-DNA (1) and Oct- -DNA (2) crystal structures
and correspond to the termini used in the computer modeling studies. The linker contains
two glycines that were included for flexibility and the two arginines that are present at
positions -1 and 1 of the Oct-1 homeodomain. (B) Sequences of 16 sites isolated after
four rounds of binding site selection(15). (C) Consensogram derived from the sequences
in (B) which indicates the percent occurrence of each nucleotide at each position. (D)
Schematic diagram illustrating the two possible orientations of the homeodomain subsite
relative to the zinc finger subsite suggested by the consensus. Mode 1 corresponds to the
configuration depicted in Figure 1.
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sequences revealed the consensus binding site 5'-TAATTANGGGNG-3' (Fig. 2C). The
5' half of this consensus, TAATTA, resembled a canonical homeodomain binding site
TAATNN (4) and matched the site (TAATNA) that is preferred by the Oct-1
homeodomain in the absence of the POU-specific domain (5). The 3' half of the
consensus, NGGGNG, resembled adjacent binding sites for fingers 2 (TGG) and 1 (GCG)
of Zif268. The guanines were more tightly conserved than the other positions in these
zinc finger subsites, and the crystal structure shows that these are the positions of the
critical side chain-base interactions (1).
The ZFHD1 consensus sequence (5'-TAATTANGGGNG-3') matched the model
that appeared most structurally feasible (6), but because of the internal symmetry of the
TAATTA subsite this sequence was also consistent with the homeodomain binding in
another orientation (Fig. 2D, compare mode 1 and mode 2). This alternative
arrangement, in which the critical TAAT is on the other strand and directly juxtaposed
with the zinc finger (TGGGCG) subsites, was considered unlikely since modeling had
suggested that this arrangement required a linker to span >20 A between the COOH-
terminus of finger 2 and the NH2-terminus of the homeodomain. To determine how the
homeodomain bound to the TAATTA sequence in the 5' half of the consensus, ZFHD1
was tested for binding to probes (5'-TAATGATGGGCG-3' and 5'-TCATTATGGGCG-
3') designed to distinguish between these orientations. ZFHD1 bound to the 5'-
.TAATGATGGGCG-3' probe with a dissociation constant of 8.4 x 10-10 M, and
preferred this probe to the 5'-TCATTATGGGCG-3' probe by a factor of 33 (Fig. 3A
compare lanes 6-10 and 11-15). This suggested that the first four bases of the consensus
sequence form the critical TAAT subsite that is recognized by the homeodomain (mode
I) and that ZFHD 1 binds as predicted in the model shown in Figure 1.
We compared ZFHD1, Oct-1 and Zif268 for their abilities to distinguish among
the Oct-l site 5'-ATGCAAATGA-3', the Zif268 site 5'-GCGTGGGCG-3', and the hybrid
binding site 5'-TAATGATGGGCG-3'. The fusion protein ZFHD1 preferred the optimal
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Figure 3. Comparison of the DNA binding specificity of ZFHD1, the Oct-i POU
domain (which contains a homeodomain and a POU-specific domain), and the three zinc
fingers from Zif268 (16). (A) The GST-ZFHD1 protein was titrated into DNA-binding
reactions containing the probe listed at the top of each set of lanes. Lanes 1, 6, 11, and 16
contain the protein at 9.8 x 10-11 M; Protein concentration was increased in 3 fold
increments in subsequent lanes of each set. The position of the protein-DNA complex is
indicated by the arrow. (B) The PA-Oct-1 POU fusion protein (17) was titrated into
parallel DNA-binding reactions as in (A), but lanes 1, 6, 11, 16 contain the protein at 2.1
x 10-12 M. The position of the protein-DNA complex is indicated by the arrow. (C) A
peptide containing Zif268 fingers 1, 2 and 3 (1) was titrated into parallel DNA-binding
reactions with lanes 1, 6, 11, 16 containing the peptide at 3.3 x 10-11 M. The position of
the protein-DNA complex is indicated by the arrow.
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hybrid site to the octamer site by a factor of 240 (Figure 3A compare lanes 1-5 and 11-
15), and did not bind to the Zif site (lanes 16-20). The POU domain of Oct-i (Fig. 3B)
bound to the octamer site with a dissociation constant of 1.8 x 10-10 M (lanes 1-5),
preferring this site to the hybrid sequences by factors of 10 (lanes 6-10) and 30 (lanes 11-
115), and did not bind to the Zif site (lanes 16-20) (7). The three fingers of Zif268 (Fig.
3C) bound to the Zif site with a dissociation constant of 3.3 x 10-10 M (lanes 16-20), and
did not bind to the other three sites (lanes 1-15). These experiments proved that ZFHD1
bound tightly and specifically to the hybrid site and displayed DNA-binding specificity
that was clearly distinct from that of either of the original proteins.
We fused ZFHD1 to a transcriptional activation domain and used transfection
experiments to determine whether the novel DNA-binding protein could function in vivo.
An expression plasmid encoding ZFHD1 fused to the COOH-terminal 81 amino acids of
the Herpes Simplex Virus VP16 protein (ZFHD1-VP16) was co-transfected into 293 cells
with reporter constructs containing the SV40 promoter and the firefly luciferase gene. To
determine whether the fusion protein could specifically regulate gene expression, we
tested reporter constructs containing two tandem copies of either the ZFHD1 site 5'-
TAATGATGGGCG-3', the octamer site 5'-ATGCAAATGA-3', or the Zif site 5'-
(GCGTGGGCG-3' inserted upstream of the SV40 promoter. When the reporter contained
two copies of the ZFHD1 site, the ZFHD1-VP16 protein stimulated the activity of the
promoter in a dose-dependent manner (8). Furthermore, the stimulatory activity was
specific for the promoter containing the ZFHD1 binding sites (Fig. 4). At levels of
protein which stimulated this promoter by 44 fold, no stimulation above background was
observed for promoters containing either the octamer or Zif sites. Thus, ZFHD1
efficiently and specifically recognized its target site in vivo.
This structure-based strategy of fusing known DNA-binding modules may
provide a general method for designing transcription factors with novel DNA-binding
specificities. Computer modeling suggests a number of other plausible arrangements for
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Figure 4. Regulation of promoter activity in vivo by ZFHD1. The 293 cells were co-
transfected with 5ug of reporter vector, lOug of expression vector, and 5 ug of pCMV-
hGH (gift of J. Parvin) used as an internal control (18). The reporter vectors contained
two tandem copies of either the ZFHD1 site (TAATGATGGGCG), the Oct-1 site
(ATGCAAATGA), the Zif site (GCGTGGGCG), or no insert. The expression vector
encoded the ZFHD1 protein fused to the COOH-terminal 81 amino acids of VP16 (+
bars), and the empty expression vector Rc/CMV was used as control (-bars). The level of
luciferase activity obtained, normalized to hGH production, was set to 1.0 for the co-
transfection of Rc/CMV with the no-insert reporter pGL2-Promoter. Bar graphs
represent the average of three independent experiments. Actual values and standard
deviation reading from left to right are: 1.00 ± .05, 3.30 + .63; 0.96 + .08, 42.2 ± 5.1; 0.76
± .07, 2.36 ± .34; 1.22 + .10, 4.22 + 1.41. Fold induction refers to the level of normalized
activity obtained with the ZFHD1-VP16 expression construct divided by that obtained
with Rc/CMV.
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hybrid proteins. Figure 5 illustrates models of a zinc finger-basic-helix-loop-helix fusion
protein (Fig. 5A) and a zinc finger-steroid receptor fusion protein (Fig. 5B) that should
recognize hybrid binding sites. In each case, the modules can be fused by a short
polypeptide linker without steric interference between the domains. This strategy could
also be extended by varying the length and sequence of the polypeptide linkers and then
using selection methods to optimize the binding affinity and specificity of the hybrid
protein.
The strategy of fusing modules can also be combined with those designed for
changing the sequence specificity of individual modules. Several DNA-binding domains
are amenable to mutational strategies for changing sequence specificity (9,10), and zinc
fingers may offer the most versatility (11). Combining structure-based design with
mutational changes in specificity would greatly expand the range of sequences that could
be targeted by hybrid domains.
The high affinity of ZFHD1 for its optimal site and the fact that ZFHD1, Oct-1,
and Zif268 all clearly preferred different sites illustrate the success of the combinatorial
approach. The specificity of the hybrid transcription factor depends upon the relatively
moderate affinity, but high sequence specificity, for the binding of a single module and
the chelate effect (12) provided by the covalent linkage of modules. The design criteria
that allowed the construction of ZFHD1 included the short length of polypeptide linker
that was required to fuse the DNA-binding domains and the absence of steric interference
between these domains.
Designed transcription factors will be useful for the targeted regulation of specific
cellular genes. Using particular DNA-binding domains in a hybrid (or adding other
domains) may allow a protein to interact with other cellular factors or to be modulated by
a particular regulatory pathway. The structure-based design of hybrid transcription
factors should facilitate the development of efficient and specific reagents for biological
research and gene therapy.
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Figure 5. Models of fusions of other DNA-binding modules. (A) A putative zinc finger-
basic-helix-loop-helix fusion. Finger 1 of Zif268 is depicted in purple, finger 2 in yellow,
and the MyoD bHLH region (19) in red and gray. The distance in angstroms between the
COOH-terminus of finger 2 and the NH2-terminus of the basic region of the bHLH
domain is indicated. (B) A putative zinc finger-steroid receptor fusion. Finger 1 of Zif268
is depicted in purple, finger 2 in yellow, and the glucocorticoid-receptor (20) in red and
gray. The distance in angstroms between the NH2-terminus of finger 2 and the COOH-
terminus of the glucocorticoid receptor is indicated. These figures were generated with
Insight II (Biosym Technologies, San Diego).
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CHAPTER V
ANALYSIS OF HOMEODOMAIN FUNCTION BY STRUCTURE-BASED
DESIGN OF A TRANSCRIPTION FACTOR
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ABSTRACT
The homeodomain is a 60 amino acid module which mediates critical protein-
DNA and protein-protein interactions for a large family of regulatory proteins. We have
used structure-based design to analyze the ability of the Oct-1 homeodomain to nucleate
an enhancer complex. The Oct-l protein regulates Herpes Simplex Virus (HSV) gene
expression by participating in the formation of a multiprotein complex (C1 complex)
which regulates a (immediate early) genes. We recently described the design of ZFHD1,
a chimeric transcription factor containing zinc fingers 1 and 2 of Zif268, a four residue
linker, and the Oct-l homeodomain. In the presence of aTIF and C1 factors, ZFHD1
efficiently nucleates formation of the C1 complex in vitro and specifically activates gene
expression in vivo. The novel sequence specificity of ZFHD1 recruits C1 complex
formation to a novel enhancer element. ZFHD1 function depends on the recognition of
the Oct-1 homeodomain surface. The results indicate that the Oct-1 homeodomain
mediates all the protein-protein interactions that are required to efficiently recruit aTIF
and C1 factors into a C1 complex. The structure-based design of transcription factors
should provide valuable tools for dissecting the interactions of DNA-bound domains in
other regulatory circuits.
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INTRODUCTION
Homeodomain proteins play central roles in the development and differentiation
of eukaryotic organisms, but a mechanistic understanding of their biological specificity
has only been achieved in a few cases (1). Like other transcription factors, homeodomain
proteins are modular, containing functionally and structurally independent domains
which determine their sequence specificity and regulatory action (activation or
repression). The DNA-binding of these proteins relies upon the 60 amino acid
homeodomain which has been extensively characterized biochemically and at the
structural level (2-6). In several studies, functional differences between two regulatory
proteins have mapped to their homeodomains, even though their DNA-binding properties
may be indistinguishable (7-12). These observations have suggested that the
homeodomain serves not only as a DNA-binding module, but also as a target for protein-
protein interactions with other factors that enhance its target specificity and effector
function (13-16).
The role of the human Oct-1 protein in the regulation of Herpes Simplex Virus
gene expression exemplifies how protein-protein interactions with the homeodomain can
determine functional specificity. Viral a or immediate early (a/IE) gene expression is
controlled by the assembly of a multiprotein complex (C1 complex) composed of Oct-l,
the viral aTIF protein (VP16, Vmw65, ICP25), and the cellular C1 factor (HCF), on the
a/1E element (5'-ATGCTAATGATATTCTTTGG-3') (17-25). The 5' portion of the
element is recognized by the Oct-1 POU domain, which is a bipartite DNA-binding
domain. The POU-specific domain binds the ATGC subsite and the associated
homeodomain binds the TAATGA subsite (26, 27). The 3' portion of the element is
recognized by aTIF and possibly by the C1 factor (26). Oct-2 has identical DNA-binding
specificity to Oct-1 but is 100-fold less efficient at complex formation (21, 22). This
difference between Oct-1 and Oct-2 in the regulation of HSV correlates with a single
amino acid difference on the surface of their homeodomains which allows aTIF to
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distinguish between them in complex assembly (13, 14). The selective recognition of the
Oct-1 homeodomain surface by aTIF exemplifies how protein-protein interactions can
confer upon two homeodomain proteins with identical DNA-binding specificity
dramatically different abilities to regulate a particular gene.
Previous studies established that the POU domain, composed of the POU-specific
domain, a 24 residue linker, and the homeodomain, was as efficient as the full length Oct-
1 protein at binding the HSV a/IE element and forming the C1 complex (21). The
isolated Oct-i homeodomain was capable of nucleating complex formation, but only
functioned at high concentrations (13, 26). The low affinity and modest specificity of the
homeodomain for DNA precluded an in vivo assay of complex formation in the absence
of the POU-specific domain.
We have used structure-based design to develop a chimeric protein, ZFHD1 (28),
that has allowed us to test whether the homeodomain of Oct-1 can efficiently mediate all
of the protein-protein interactions necessary to recruit aTIF and the C1 factor into a
functional enhancer complex. ZFHD1 contains the Oct-1 homeodomain fused to two
zinc finger domains. The chimeric protein possesses high affinity and specificity for a
novel DNA site, permitting the study of homeodomain function in physical isolation from
the POU-specific domain and free of competition in vivo with the endogenous Oct-1
protein.
MATERIALS AND METHODS
Gel electrophoretic mobility shift assays. DNA binding reactions contained 0.4 - 0.8
ng DNA probe, 75 ng sonicated salmon sperm DNA, 10 mM Hepes (pH 7.9), 0.5 mM
EDTA, 50 mM KCl, 0.75 mM DTT, 4% Ficoll-400, 300 g/ml of bovine serum albumin,
and the appropriate purified proteins or chromatographic fraction in a total volume of 10
gl. Reactions were incubated at 30°C for 30 min and resolved in 4% nondenaturing
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polyacrylamide gels (13). Protein-DNA complexes and the free DNA were quantitated
using a Molecular Dynamics PhosphorImager with ImageQuant 3.22 software.
Production of recombinant proteins. The design and characterization of the GST-
ZFHD1 fusion has been described (28). GST-ZFHD1 variants containing point
mutations on the surface of the homeodomain were generated by PCR amplification of
appropriate fragments using the expression vectors described below as substrates,
followed by cloning the amplified fragments into the BamHI site of pGEX2T
(Pharmacia) to generate in-frame fusions to GST. GST-ZFHD1 variants were expressed
and purified as described (28).
Transient Transfection Assays; Reporter vectors were constructed by cloning the
following fragments into the Xho I and Kpn I sites of pGL2-Promoter (Promega): a/E:
5'-GGTACCATGCTAATGATATTCTTrGG CTGCAGATGCTAATGATATTCTTTGG
CTCGAG-3'; o/IE-ZF: 5'-GGTAC CGCCCTAGTAATGATATTCTT7 GG CTGCAGCG
CCCTAGTAATGATATTCTIGGCTCGAG-3'; a/IE-ZF-3'MT: 5'-GG TACXCGCCCTA
GTAATGCTG TCTTGG CTGCAGCGCCCTAGTAATGCTGTTCITGG CTCGAG
-3'. These reporters were subsequently digested with Bgl II and Dsa I, end-filled with the
Klenow fragment of E. Coli DNA Pol I, and religated to remove the promoter region
upstream of the TATA box that contains the 21 base pair repeat elements of the SV40
early promoter (29). The ZFHD1 expression vector was constructed by cloning a
fragment encoding the hemagglutinin epitope MYPYDVPDYA (30) and ZFHD1 (28)
into the Not I and Apa I sites of Rc/CMV(Invitrogen). Vectors expressing variants of
ZFHD1 that contained mutations on the homeodomain surface were constructed as
follows: The ZFHDl-encoding fragment was cloned into the Not I and Apa I sites of
pBSKII+(Stratagene) and ssDNA was produced to be used as the substrate for
oligonucleotide-directed mutagenesis (31) using VCSM13 helper phage (Stratagene)
according to the manufacturer's protocol. Mutagenesis was performed as described (31)
except that T7 DNA Polymerase was used in the initial polymerization step (32).
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Oligonucleotides used for mutagenesis contained -10 nucleotides on each side of the
mutation-specific bases. Products of the mutagenesis reactions were screened by
dideoxysequencing, and the desired fragments were isolated and cloned into the Not I and
Apa I sites of Rc/CMV. The aTIF expression vector, pCMV1TIF1, containing the aTIF
gene under control of the CMV promoter was a gift of J.L.C. McKnight. The 293 cells
were transfected and the results quantitated as described (28).
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RESULTS
Recently we described the design and characterization of ZFHD1, a transcription
factor composed of zinc fingers 1 and 2 from Zif268 fused to the Oct-l homeodomain
with a four residue linker (28). ZFHD 1 displayed DNA-binding specificity in vitro that
was distinct from that of either parental protein and, when fused to an acidic activation
domain, activated transcription in a sequence specific manner in vivo. Although the
optimal ZFHD1 binding site (28) has a different arrangement, computer modeling
suggested that the linker between finger 2 and the homeodomain might also permit the
ZFHD1 protein to bind DNA tightly in a configuration that would allow the
homeodomain to be accessible for nucleation of a C1 complex. In this arrangement,
finger 1 would bind the CNC triplet (CNCCCNNNTAATNN), finger 2 the CCN triplet
(CNCCCNNNTAATNN), and the homeodomain would recognize the TAATNN
sequence (CNCCCNNNTAATNN). This putative arrangement was used to design the
novel a/IE-ZF element (Figure 1), which represents a fusion of this putative ZFHD1
binding site with the 3' portion of the a/E element.
The Oct- 1 POU domain and ZFHD 1 were tested for binding to the a/IE and a/IE-
ZF elements, and for the ability to nucleate C1 complex formation (Figure 2). As
expected, the POU domain bound the a/lE element efficiently and readily formed the C1
complex upon addition of the aTIF and C1 factors (lanes 1 and 2). In contrast, the POU
domain had a significantly lower affinity for the a/IE-ZF element, and did not efficiently
nucleate the C1 complex on this site (lanes 3 and 4). At high protein concentrations, the
extent of POU domain binding to the the a/IE-ZF element was comparable to that
observed on the a/IE element; however, C1 complex formation was significantly less
efficient on the a/IE-ZF element (lanes 9-12). This probably reflects binding of the POU-
specific domain to sequences in the 3' portion of the a/IE-ZF element, analagous to that
which has been observed for a related a/IE element which also lacks an ATGC binding
site (34). Binding of the POU-specific domain to 3' sequences would be expected to
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Figure 1. Schematic representation of the C1 complex. In the natural a/IE element
(top), the Oct-i POU-specific domain (green) recognizes the ATGC subsite, the
homeodomain (red) binds the TAATGA subsite, and the remainder of the element
(shaded base-pairs) is recognized by the aTIF and C1 factors. Residues on the surface of
the homeodomain which were mutated in this study are shown on helix 1 (N11, K18, and
E22), helix 2 (E30), and in the loop between helices 2 and 3 (N39). The a/IE element
was converted to the a/IE-ZF element (bottom) by replacing the subsite for the POU-
specific domain with binding sites for zinc finger 1 (purple) and zinc finger 2 (green) of
ZFHD1 which recognize the CGC and CCT triplets, respectively. The depicted topology
of protein-DNA complexes is based on the coordinates of Klemm et al. (1994) (6),
Pavletich and Pabo (1991) (33), and computer modeling (28).
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Figure 2. Comparison of the POU domain and ZFHD1 for DNA-binding specificity and
ability to participate in C1 complex formation. DNA-protein binding reactions were done
as described in Materials and Methods with a probe containing either the a/IE (5'-
GTGCATGCTAATGATATCTTGG-3') (HSVaO probe (21)) or the a/IE-ZF (5'-CGC
CCTAGTAATGATATTCTTTGG-3') element as indicated. The Protein A-Oct-1 POU
fusion protein (200 pg, lanes 1-4; 500 pg lanes 9 and 10; 1000 pg lanes 11 and 12) or the
GST-ZFHD1 fusion protein(200 pg) were incubated in the absence (-) or presence (+) of
15 ng PA-aTIF and 1 gl of a chromatographic fraction containing the HeLa cell C1 factor
(13) as indicated. The reactions contained subsaturating concentrations of aTIF and C1
factor. The positions of the multiprotein C1 complex as well as the POU-DNA and
ZFHD 1-DNA complexes are indicated with arrows.
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sterically interfere with aTIF and C1 factor association.
ZFHD1 displayed a clear preference for the aJIE-ZF element. The designed factor
did not bind the natural a/IE element or nucleate complex formation at this site (lanes 5
and 6), but ZFHD 1 efficiently bound the ajIE-ZF element and, upon addition of aTIF and
C1, efficiently nucleated complex formation (lanes 7 and 8). Most importantly,
comparable concentrations of the POU domain and ZFHD1 generated comparable DNA-
binding activity and efficiency at forming the C1 complex at their preferred sites. This
argues strongly that the 60 amino acids in the homeodomain provide all the Oct-l-
mediated protein-protein interactions necessary for efficient C1 complex formation.
Furthermore, the results clearly indicate that the designed chimeric protein could be used
to recruit the enhancer complex to a novel site which is not efficiently recognized by the
wild-type Oct-l protein.
To determine whether ZFHD1 could target enhancer complex formation in vivo
to the a/E-ZF element, transient transfection experiments were performed (Figure 3).
293 cells were cotransfected with a vector expressing aTIF and a reporter construct
containing two tandem copies of either the a/IE or a/IE-ZF element upstream of a
minimal promoter and the luciferase gene (see Materials and Methods). Cotransfection
of the aTIF expression vector and the a/IE reporter resulted in a 31-fold activation,
reflecting assembly of the C1 complex with the endogenous Oct-1 and C1 factors. Both
of these cellular factors are quite abundant and are probably not limiting for activity. In
contrast, cotransfection of aTIF and the a/IE-ZF reporter resulted in only a 4-fold
activation, presumably reflecting the reduced ability of the endogenous Oct-1 to bind to
the a/IE-ZF element and form a C1 complex. Cotransfection of vectors expressing
ZFHD1 and aTIF with the a/IE-ZF reporter resulted in a 34-fold activation. Further
controls confirmed that activation was a consequence of aTIF association and C1
complex assembly. A third reporter contained a mutant a/IE-ZF element, designed to
support ZFHD1 binding but containing nucleotide substitutions (21) expected to
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abrogate aTIF binding and complex assembly (a/E-ZF-3'MT:CGCCCTAGTAATG CT
TTCTTT). Cotransfection of aTIF and ZFHD1 with this reporter resulted in only a 4-
fold activation. These results demonstrate the affinity and specificity of ZFHD1 for the
a/IE-ZF element and the ability of ZFHD1 to recruit aTIF and C1 factors in vivo through
interactions with the homeodomain.
The ability of ZFHD1 to nucleate complex formation and activate transcription at
the a/IE-ZF element should be dependent on the recognition of the Oct-1 homeodomain
surface that is solvent exposed when the domain binds DNA (13, 14). Several mutations
on the surfaces of helices 1 and 2 of the homeodomain have been previously
characterized in vitro for their effect on the cooperative interaction with aTIF and for
their effect on C1 complex assembly (13). Five of these mutations were individually
introduced into ZFHD 1 and then assayed, in vivo and in vitro, for complex formation on
the a/IE-ZF element. Single amino acid substitutions at positions 18, 22, and 30 on the
homeodomain surface have been shown to severely reduce the ability of Oct- to
participate in complex assembly, while substitutions at positions 11 and 39 have milder
effects. As expected, these mutations had similar effects in the context of the chimeric
ZFHD1 protein without affecting the DNA-binding characteristics of the designed protein
(Figure 4A and 4B), confirming that the arrangement of the homeodomain in the
ZFHD1/DNA complex mimics its arrangement in the POU domain/DNA complex. As
compared to the 34-fold activation observed with the wild-type ZFHD1, the activation
observed with the variants was 18-fold (N11A), 4-fold (K18E), 4-fold (E22A), 4-fold
(E30Q), and 30-fold (N39H) (Figure 4A). The extent of in vitro complex formation for
the variants directly paralleled their activity in vivo (Figure 4B). As compared to the
level seen with the wild-type ZFHD1, the extent of C1 complex formed was 65%
(NllA), 4% (K18E), 4% (E22A), undetectable (E30Q), and 102% (N39H) (Figure 4B).
The results confirm that recognition of the surface of the Oct-i homeodomain is critical
for the assembly of the C1 complex in vivo.
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Figure 3. Transcriptional activity of aTIF and ZFHD1 in vivo. The 293 cells were
cotransfected with 5 g of reporter vector, 10.05 fig total of expression vector, and 5 jig
of pCMV-hGH used as an internal control. Where indicated, 10 gig of a vector expressing
ZFHD1 (+) or the equivalent amount of the empty Rc/CMV vector (-) were cotransfected
with (+) or without (-) 50 ng of pCMV1TIF1 (aTIF) . Reporter vectors contained two
tandem copies of the a/IE element (5'-ATGCTAATGATATTCTTTGG-3'), the o/jIE-ZF
element (5'-CGCCCTAGTAATGATATTCTFTGG-3'), or the a/IE-ZF-3'MT element (5'-
CGCCCTAGTAATG CTGTTCTTTGG-3'). The amount of luciferase activity obtained,
normalized to hGH production, was set to 1.0 for the cotransfection of Rc/CMV with the
adE reporter. Each bar represents the average of three independent experiments. Actual
values and standard deviation, reading from left to right, are: 1.00 + 0.26; 31.00 +4.17;
0.97 + 0.26; 3.97 ± 0.46; 0.83 ± 0.03; 28.17 ± 4.53; 0.57 + 0.07; and 2.37 + 0.26. Fold
induction refers to the ratio of normalized activity obtained in the presence and absence
of aTIF expression.
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Figure 4. ZFHD1-mediated C1 complex formation depends upon recognition of the
homeodomain surface. (A) The 293 cells were cotransfected with 5 ig of reporter vector,
10.05 jig total of expression vector, and 5 gig of pCMV-hGH used as an internal control.
Ten jig of ZFHD1 expression vector encoding wild-type ZFHD1 (WT) or the indicated
variants were cotransfected with the reporter containing the a/IE-ZF elements with (+) or
without (-) 50 ng of pCMV1TIF1 (aTIF). Luciferase activity was normalized as in
Figure 2. Each bar represents the average of three independent experiments. Actual
values and standard deviation, reading from left to right, are: 0.83 + 0.03; 28.17 + 4.53;
1.03 + 0.30; 18.73 + 2.63; 0.77 + 0.33; 3.30 + 0.93; 0.80 ± 0.23; 3.23 + 0.57; 0.73 + 0.26;
2.63 + 0.28; 0.90 ± 0.15; and 26.83 + 3.10. Fold induction refers to the ratio of
normalized activity obtained in the presence and absence of aTIF expression.
Comparable levels of expression of all ZFHD 1 variants were confirmed by the presence
of a gel shift activity, present only in extracts of transfected cells, that was reactive to the
aHA monoclonal antibody 12CA5 (gift of K. Moberg). (B) The GST-ZFHD1 fusion
protein (200pg) or variants containing the indicated substitutions were incubated in DNA-
protein binding reactions in the absence (-) or presence (+) of 15 ng PA-aTIF and 1 il of
a chromatographic fraction containing the HeLa cell C1 factor. The probe contained the
a/IE-ZF (5'-CGCCCTAGTAATGATATTCTTTGG-3') element, and the reactions
contained subsaturating concentrations of aTIF and C1 factor. The positions of the
multiprotein C1 complex and of the ZFHD 1-DNA complexes are indicated with arrows.
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DISCUSSION
Structure-based design can provide valuable tools for studying the biological
functions of transcription factors. We have used this strategy to dissect the Oct-1 POU
domain and examine the role of the homeodomain in HSV a/IE gene regulation. The
ability of the chimeric ZFHD1 protein to nucleate the C1 complex on the a/IE-ZF
element in vitro with efficiency comparable to that of the intact POU domain is the best
evidence to date that the Oct-1 homeodomain alone provides all of the protein-protein
interactions that Oct-1 contributes to C1 complex formation. The primary role of the
POU-specific domain in the formation of the wild-type C1 complex is to enhance the
affinity and specificity of homeodomain-DNA association. The POU-specific domain
can be replaced by the two zinc fingers in ZFHD1 without compromising the ability to
nucleate C1 complex formation.
Both Oct-1 and C1 factor are abundant nuclear proteins that are expressed in
most, if not all, cell types. The use of the a/IE-ZF element and the designed ZFHD1
factor permitted the assay of C1 complex formation in vivo, independent of endogenous
Oct-i activity. ZFHD 1 stimulated gene expression in vivo through the a/IE-ZF element
to a level (34-fold) comparable to that observed at the a/IE element with the endogenous
Oct-1 protein (31-fold). This activity was dependent on 1) cotransfection of ZFHD1
with aTIF, 2) sequences 3' to the ZFHD1 binding site in the a/IE-ZF element which are
recognized by aTIF and possibly the C1 factor, and 3) on the appropriate amino acids on
the surface of the homeodomain which are recognized by aTIF (13). This specificity
indicates that of the 743 amino acids in the Oct-1 protein, the 60 amino acid
homeodomain is sufficient to nucleate C1 complex formation in vivo when efficiently
targeted to the appropriate DNA sequence.
The structure-based design of ZFHD1 has permitted this analysis because the
unique DNA binding specificity of the designed factor targets the homeodomain to a
specific DNA site without disrupting the homedomain-DNA interaction. Related
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structure-based strategies should provide useful new approaches to the study of gene
regulation in many other systems. The use of ZFHD1 for the analysis of homeodomain
function provides a first example of how these design strategies can be used to
characterize the biological activity of DNA-bound domains.
The chimeric ZFHD1 protein may also be useful for dissecting the role of the
Oct-i homeodomain in other regulatory contexts. Oct-i is important for the regulated
expression of the snRNA genes which are ubiquitously expressed, the histone H2B gene
which is expressed in a cell-cycle-specific fashion, and the interleukin-2 and
immunoglobulin genes which are expressed only in lymphoid tissues (35). It is possible
that regulatory specificity in some or all of these contexts will be determined by
recognition of the homeodomain surface by cellular homologues of aTIF. Indeed, the
unique activity of the Oct-1 binding site in B cells has recently been attributed to a B-cell
specific factor, OCA-B (Bobl, OBF-1), which associates with the Oct-1 POU domain
and contains an activation domain (36-38).
The recognition of the homeodomain surface mediates functional specificity in a
number of other systems. In Drosophila, for example, the differing abilities of the
Ultrabithorax (Ubx) and Antennapedia homeodomain proteins to regulate the
decapentaplegic gene is determined by their differing potentials for cooperative enhancer
binding with the extradenticle (exd) protein (15, 16). The interaction of Ubx with exd is
dependent on residues 22, 24, and 56 on the Ubx homeodomain surface (numbering
scheme used in the homeodomain structural studies), and on the region C-terminal to the
Ubx homeodomain (15). Cooperative interaction with exd also appears to modulate the
target specificity of the abdominal-A and engrailed homeodomains (16). In human cells,
the surfaces of helices one and two of the Phoxl homeodomain are important for the
ability of the protein to recruit SRF and signal-responsive accessory factors to the c-fos
serum response element (39). These studies underscore the importance of being able to
dissect the specific protein-DNA and protein-protein interactions that occur at the
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homeodomain surfaces. Because the structure and DNA-docking of homeodomains are
so highly conserved (4), it may be possible to design ZFHD1-analogs with other
homeodomains.
The study of transcription factor function has benefited greatly from the
construction of chimeric proteins. For example, investigations of activation domains
were greatly facilitated by fusing them to heterologous DNA-binding domains which
would target the effector domain to a "neutral" element that would not support the
binding of competing activities (40, 41). The success of these studies depended on the
ability of activation domains to function when presented in a variety of spatial contexts.
For the targeting of a DNA-binding domain to a novel site, one must insure that the
chimeric protein permits the specific orientation that is required for DNA binding.
Structure-based design provides a powerful technique for retargeting individual DNA
binding domains in a stereochemically precise way.
An attractive feature of the structure-based design strategy is that it offers the
opportunity to change binding specificity without introducing any mutations at the
protein-DNA interface. For some domains, such mutations may be difficult to obtain
(42), or may inadvertently influence the interaction with other factors (43-45). Computer
modeling studies (28) suggest that the rational design of chimeric DNA-binding domains
should be possible for many different DNA-binding modules, facilitating
characterization of the protein-protein interactions that may define their biological
activity.
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EPILOGUE
FUTURE PROSPECTS FOR DESIGNED TRANSCRIPTION FACTORS
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The most powerful potential application for designed DNA-binding proteins is the
targeted regulation of specific genes. The use of such factors will only be made practical
by the development of generalizable techniques that address several issues, including
specificity, efficiency, regulatability, and delivery (i. e. for gene therapy). Because of the
modularity of transcription factors, domains that mediate effector function (activation or
repression) or regulatability (e.g. ligand-responsive nuclear localization) can be borrowed
from natural factors. Therefore, designing a specific transcription factor may, to a first
approximation, amount to attaching such domains to a DNA binding domain with a
desired sequence specificity.
Can a domain be designed or selected to recognize any sequence? At present, the
answer is an optimistic maybe. The first wave of zinc finger phage display experiments
demonstrated that new fingers with new specificities could be selected (Rebar and Pabo,
1994; Jamieson et al., 1994; Choo and Klug, 1994ab). But they also showed that a finger
could not be selected for the recognition of some base-pair triplets. These results may
:reflect an inherent limitation in the sequence-recognition capability of C2H2 zinc fingers,
but it is too early to judge whether other factors (such as contextual effects) were at play.
Similar experiments with zinc fingers from different proteins should illuminate how wide
a range of sequences can be used to select fingers that bind with high affinity and
specificity. It is also possible that selection experiments conducted with other domains
might expand the diversity of sequences that can be recognized.
The structure-based design of transcription factors provides an alternative
approach. Because the technique does not disrupt the wild-type protein-DNA interface it
can take advantage of the natural DNA-binding specificity that a given domain has
acquired during evolution under selection for function. A particular target sequence
could be inspected for the presence of a proper arrangement of binding sites for
structurally-characterized domains. These domains could then be fused and the affinity
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and specificity of the chimeric domain tested. This strategy should complement the
selection schemes if the technique can be extended.
The use of other DNA-binding domains to design chimeric proteins should be
attempted. It would be valuable to test whether homologous domains behave in similar
ways in chimeric domains, and whether there is generality in the structural prediction. Is
ZFHD1 a model for the fusion of any two C2H2 zinc fingers to any homeodomain? It is
unlikely that this is universally true, but there may be some possibility for establishing
rules for fusing domains. For example, all homeodomains may not behave similarly in a
chimeric protein, but perhaps all POU-homeodomains will because they are much more
homologous to each other than to other homeodomains. One would hope that the
structural and biochemical characterization of a few members of a transcription factor
family would allow the application of general principles to many members of the family.
The computer modeling presented in Chapter 4 suggested that the design of
chimeric proteins may be possible for other domains. Many DNA-binding domains fold
into compact structures that have termini accessible for fusion when bound to DNA. As
structural information accumulates for many DNA-binding proteins, it should be
straightforward to test which combinations of domains are compatible.
The affinity and specificity of a designed chimeric domain might be modulated by
residues in the linker that connects two domains. Since the linker might be juxtaposed to
the DNA, residues may be able to contact the sugar-phosphate backbone, or make base-
specific contacts, in either the major or minor grooves. The linker may also determine
specificity by constraining the relative orientations of the fused domains such that the
chimeric protein would be specific for a particular arrangement of subsites. The linker
may accomplish this by imposing a length restriction between domains, and longer
linkers may position the domains through direct protein-protein interactions. One way to
explore this possibility would be to randomize the linker in ZFHD1 between finger 2 and
the homeodomain, and then select for the variant that would bind the optimal ZFHD1 site
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with highest affinity. Variants could also be selected for binding to a site of the form
used in Chapter 5 for C1 complex formation. Any demonstration that the linker could
influence specificity would demonstrate a general potential that could be exploited in
other proteins.
For targeted gene regulation, it may not be necessary to have the capacity to bind
to any sequence in the genome. Because transcription factors can function in a distance-
independent and orientation-independent manner, one might only need to inspect the
1DNA sequence within 1000 base-pairs or so 5' or 3' to the initiation site for a gene-
specific sequence which could serve as the target in a design scheme. For example, one
might identify several occurrences of a TAAT homeodomain core binding site in the
vicinity of the initiation site. Sequences adjacent to one of the TAAT subsites might
resemble the subsite for a different domain which could be fused to the homeodomain in
a sterically compatible arrangement. Alternatively, the adjacent sequences might be used
as the target in phage display experiments for the selection of a zinc finger that could be
fused to the homeodomain in the appropriate register. Regulation by designed factors
would not necessarily require any knowledge of the normal mechanisms that regulate the
gene in question.
A designed regulatable transcription factor might be used to affect the expression
of a particular gene in an inducible, reversible manner, either in a cell line or a transgenic
organism. An advantage of using designed transcription factors for gene regulation is
that regulation could be conferred without irreversibly altering portions of the coding
region of the gene under study, as is done in embryonic stem cell gene targeting (Bronson
and Smithies, 1994). Some knockout methods allow temporal or spatial control of the
deletion event (Gu et al., 1994), but they are not reversible. If made regulatable, a
designed factor might be useful, for example, for the study of genes during particular
temporal windows in the lifetime of an organism in situations where presence of the gene
product is desired both before and after the window.
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Until it is demonstrated that a factor can be designed to regulate an endogenous
gene, it is difficult to invoke applications with confidence. For this experiment, any
endogenous gene which can be assayed easily and quantitatively could be targeted. For
example, the human growth hormone (hGH) gene, which is normally only expressed in
the pituitary, might be used. The DNA sequence in the vicinity of the transcription
initiation site is known (DeNoto et al., 1981). Expression vectors encoding hGH are
often used as efficiency controls in transient transfection assays, and hGH is secreted into
the medium and measured easily with readily available RIA kits (Selden et al., 1986).
Any number of genes could be used for this experiment, and it would be practical to
demonstrate the function of a designed factor in a tissue culture setting before introducing
it into an organism. It would be important to consider how one might detect the
inadvertent activity of the designed factor at genomic loci other than the one targeted.
Apart from evaluating the gross toxicity of the factor, the best one might be able to do is
to assay the activity of control elements that contain sequences that are related to the
target but should not bind the factor.
Therapeutic applications of designed transcription factors might become possible,
either for the activation of expression of a particular desired gene product, or for the
inhibition of expression of a disease-causing gene. Such applications would depend upon
systems that would ensure the safe and efficient delivery of factors, and progress is being
made in these areas for other gene therapy approaches (Mulligan, 1993). In the
meantime, there exists the opportunity to focus on the possibilities for manipulating
protein-DNA interactions to achieve desired specificities.
155
REFERENCES
Bronson, S.K., and 0. Smithies. 1994. Altering mice by homologous recombination
using embryonic stem cells. J. Biol. Chem. 269: 27155-27158.
Choo, Y. and A. Klug. 1994. Selection of DNA binding sites for zinc fingers using
rationally randomized DNA reveals coded interactions. Proc. Natl. Acad. Sci. USA 91:
1.1168-11172.
Choo, Y. and A. Klug. 1994. Toward a code for the interactions of zinc fingers with
I)NA: selection of randomized fingers displayed on phage. Proc. Natl. Acad. Sci. USA
91: 11163-11167.
I)eNoto, F.M., D.D. Moore, and H.M. Goodman. 1981. Human growth hormone DNA
sequence and mRNA structure: possible alternative splicing. Nucl. Acids Res. 9: 3719-
3730.
Gu, H., J.D. Marth, P.C. Orban, H. Mossmann, K. Rajewsky. 1994. Deletion of a DNA
Polymerase gene segment in T cells using cell type-specific gene targeting. Science
265: 103-106.
Jamieson, A. C., S.-H. Kim, and J.A. Wells. 1994. In vitro selection of zinc fingers with
altered DNA-binding specificity. Biochemistry 33:5689-5695.
Mulligan, R.C. The basic science of gene therapy. 1993. Science 260: 926-932.
Rebar, E. and C.O. Pabo. 1994. Zinc finger phage: Affinity selection of fingers with new
I)NA-binding specificities. Science 263:671-673.
Selden, R.F., K. Burke-Howie, M.E. Rowe, H.M. Goodman, and D.D. Moore. 1986.
Human growth hormone as a reporter gene in regulation studies employing transient gene
expression. Mol. Cell. Biol. 6: 3173-3179.
156
BIOGRAPHICAL NOTE
Joel L. Pomerantz
EDUCATION
Massachusetts Institute of Technology Ph.D., Biology, 1995
September 1991-present
Department of Biology
Thesis Advisor: Phillip A. Sharp, Ph.D.
Harvard Medical School, Boston, MA M.D. candidate
September 1989-present
Harvard-M.I.T. Division of Health Sciences and Technology
M.D.-Ph.D. Program, Medical Scientist Training Program
Sterling Winthrop Research Fellow in Health Sciences and Technology, 1992-1993
Brandeis University, Waltham, MA B.A., 1989
September 1985-May 1989
summa cum laude, with Highest Honors in Biochemistry
Phi Beta Kappa, elected 1988
Julian J. and Helen R. Behr Scholarship Prize, 1989
Elihu A. Silver Prize, 1988
Nathan and Bertha Richter Award, 1988
CRC Press Freshman Chemistry Achievement Award, 1986
Justice Brandeis Scholar, 1985-1989
Undergraduate Thesis Advisor: Ranjan Sen, Ph.D., Dept. of Biology
POSITIONS
June 1990-August 1991
May 1987-September 1987
Research Assistant
Massachusetts Institute of Technology, Cambridge, MA
Laboratory of Phillip A. Sharp, Ph.D.
Summer Student/Technician
Brigham and Women's Hospital,
Harvard Medical School, Boston, MA
Laboratory of K. Frank Austen, M.D.
TEACHING EXPERIENCE
7.60 Cell Biology of the Nucleus, Spring 1993, MIT
7.02 Introductory Biology Laboratory, Spring 1994, MIT
Graduate Teaching Assistant
Graduate Teaching Assistant
PUBLICATIONS
Pomerantz, J.L., C.O. Pabo, and P.A. Sharp. 1995. Analysis of homeodomain function
by structure-based design of a transcription factor. Proc. Natl. Acad. Sci.USA, in press.
157
Pomerantz, J.L., P.A. Sharp, and C.O. Pabo. 1995. Structure-based design of
transcription factors. Science, 267, 93-96.
Kristie, T.M., J.L. Pomerantz, T.C. Twomey, S.A. Parent, And P.A. Sharp. 1995. The
cellular C1 factor of the herpes simplex virus enhancer complex is a family of polypeptides.
Journal of Biological Chemistry, 270, 4387-4394.
Pomerantz, J.L., and P.A. Sharp. 1994. Homeodomain determinants of major groove
recognition. Biochemistry, 33, 10851-10858.
Pomerantz, J.L., T.M. Kristie, and P.A. Sharp. 1992. Recognition of the surface of a
homeo domain protein. Genes & Development 6, 2047-2057.
Pomerantz, J.L., F. Mauxion, M. Yoshida, W.C. Greene, and R. Sen. 1989. A second
sequence element located 3' to the NF-kB binding site regulates IL-2 receptor-alpha gene
induction. Journal of Immunology 143, 4275-4281.
Rothenberg, M.E., J.L. Pomerantz, W.F. Owen, Jr., S. Avraham, R.J. Soberman, K.F.
Austen, and R.L. Stevens. 1988. Characterization of a human eosinophil proteoglycan,
and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and
granulocyte/macrophage colony stimulating factor. Journal of Biological Chemistry 263,
13901-13908.
INVENTIONS AND PATENTS
Chimeric Transcription Factors
Inventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
Patent Application filed on December 29, 1994
158
